

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/035648 A1

(51) International Patent Classification⁷: **C07D 417/10**,
A61K 31/433, A61P 31/04

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
Mersey, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(21) International Application Number: PCT/GB02/04796

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/330,589 25 October 2001 (25.10.2001) US

(71) Applicant (for all designated States except MG, US): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GRAVESTOCK,
Michael, Barry** [GB/US]; 35 Gatehouse Drive, Waltham,
MA 02451 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.


(54) Title: ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY




(I)




(Q1)



(Q2)



(TAa1)



(TAa2)

(57) Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or HET is an N-linked 6-membered di-hydro-heteroaryl ring; Q is, for example, Q1 or Q2: wherein R² and R³ are independently hydrogen or fluoro; T is, for example, (TAa1) or (TAa2): wherein R^{4h} and R^{5h} are independently selected, for example, from hydrogen, halo, trifluoromethyl, cyano, nitro and (1-4C)alkoxy; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.



WO 03/035648 A1

ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY

The present invention relates to antibiotic compounds and in particular to antibiotic compounds containing a substituted oxazolidinone ring. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.

Gram-positive pathogens, for example Staphylococci, Enterococci, and Streptococci are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.

The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with nephrotoxicity and ototoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β -lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H.influenzae and M.catarrhalis.


Certain antibacterial compounds containing an oxazolidinone ring have been described in the art (for example, Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165). Such antibacterial oxazolidinone compounds with a 5-acetamidomethyl sidechain may be subject to mammalian peptidase

- 2 -

metabolism. Furthermore, bacterial resistance to known antibacterial agents may develop, for example, by (i) the evolution of active binding sites in the bacteria rendering a previously active pharmacophore less effective or redundant, (ii) the evolution of means to chemically deactivate a given pharmacophore and/or (iii) the development and/or up-regulation of efflux mechanisms. Therefore, there remains an ongoing need to find new antibacterial agents with a favourable pharmacological profile, in particular for compounds containing new pharmacophores.

We have discovered a new class of antibiotic compounds containing an aryl substituted oxazolidinone ring in which the aryl ring is itself further substituted. These compounds have useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against *E. faecium* strains resistant to both aminoglycosides and clinically used β -lactams, but also to fastidious Gram negative strains such as *H. influenzae*, *M. catarrhalis*, *Mycoplasma* spp. and chlamydial strains.

Accordingly the present invention provides a compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,



(I)

wherein

HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, containing either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on a C atom, other than a C atom adjacent to the linking N atom, by an oxo or thioxo group; and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by a substituent R_s wherein;

R_s is selected from the group:

(R_{sa}): halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkylcarbonylamino, (1-4C)alkylthiocarbonylamino,

- 3 -

(1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH- or (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2);

or R_s is selected from the group

(R_{sb}): (1-4C)alkyl group which is optionally substituted by one substituent selected from

- 5 hydroxy, (1-4C)alkoxy, amino, cyano, azido, (2-4C)alkenyloxy, (1-4C)alkylcarbonyl, (1-4C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkyl-SO₂-NH-, (1-4C)alkylcarbonylamino, (1-4C)alkylthiocarbonylamino, (1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH-, (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2), (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or an N-linked
- 10 5-membered heteroaryl ring, which ring contains either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on a carbon atom by an oxo or thioxo group; and/or the ring is optionally substituted on a carbon atom by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom (provided that the ring is not thereby
- 15 quaternised) by (1-4C)alkyl;

or R_s is selected from a group of formula (R_{sc1}) to (R_{sc3}) :-

(R_{sc1}): a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen or carbon atom; or

- 20 (R_{sc2}): a saturated or unsaturated 5-membered monocyclic ring containing 1 heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom if the ring is not thereby quaternised, or a ring carbon atom; or

(R_{sc3}): a saturated or unsaturated 6- to 8-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a

- 25 ring nitrogen atom if the ring is not thereby quaternised, or a ring carbon atom;

wherein said rings in (R_{sc1}) to (R_{sc3}) are optionally substituted on an available carbon atom by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, amino, cyano, azido, (2-4C)alkenyloxy, (1-4C)alkylcarbonyl, (1-4C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkyl-SO₂-NH-, (1-4C)alkylcarbonylamino,

- 30 (1-4C)alkylthiocarbonylamino, (1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH-, (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2), (3-6C)cycloalkyl or (3-6C)cycloalkenyl;

- 4 -

or Rs is selected from the group

(Rsd): cyano, nitro, azido, formyl, (1-4C)alkylcarbonyl or (1-4C)alkoxycarbonyl;

and wherein at each occurrence of an Rs substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (Rsa), (Rsb) or (Rsc1) to (Rsc3) each such moiety is

5 optionally further substituted on an available carbon atom with one or more substituents independently selected from F, Cl and Br and/or by one cyano group;


and/or which ring is optionally substituted on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl; or

10 HET is an N-linked 6-membered di-hydro-heteroaryl ring containing up to three nitrogen heteroatoms in total (including the linking heteroatom), which ring is substituted on a suitable C atom, other than a C atom adjacent to the linking N atom, by oxo or thioxo and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by one or two substituents Rs, wherein Rs is as hereinbefore defined, and/or


15 on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

and wherein at each occurrence of alkyl, alkenyl and cycloalkyl HET substituents, each is optionally substituted with one or more substituents independently selected from F, Cl and Br and/or by one cyano group;


20 Q is selected from Q1 to Q10 :-




Q1




Q2




Q3



Q4




Q5




Q6

25


- 5 -




Q7



Q8



Q9



Q10

wherein R^2 and R^3 are independently hydrogen or fluoro;

wherein A_1 is carbon or nitrogen; B_1 is O or S (or, in Q9 only, NH); X_q is O, S or N- R^1 (wherein R^1 is hydrogen, (1-4C)alkyl or hydroxy-(1-4C)alkyl); and wherein


- 10 in Q7 each A_1 is independently selected from carbon or nitrogen, with a maximum of 2 nitrogen heteroatoms in the 6-membered ring, and Q7 is linked to T via any of the A_1 atoms (when A_1 is carbon), and linked in the 5-membered ring via the specified carbon atom, or via A_1 when A_1 is carbon; Q8 and Q10 are linked to T via either of the specified carbon atoms in the 5-membered ring, and linked in the benzo-ring via either of the two specified carbon
- 15 atoms on either side of the linking bond shown; and Q9 is linked via either of the two specified carbon atoms on either side of the linking bond shown;

T is an optionally substituted C-linked (fully unsaturated) 5-membered heteroaryl ring system containing 1, 2 or 3 heteroatoms drawn in combination from O, N, or S, optionally substituted, by one or more substituents independently selected from R^{4h} , R^{5h} and R^{6h}


- 20 defined hereinafter;

T is preferably selected from the following groups of formula (TAa1) to (TAa6) below (wherein AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are defined hereinbelow);


- 6 -




(TAa1)




(TAa2)




(TAa3)



(TAa4)



(TAa5)



(TAa6)

5

wherein :


R^{6h} is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;

- 10 R^{4h} and R^{5h} are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl, benzyloxy-(1-4C)alkyl, (2-4C)alkanoylamino, -CONR_cR_v and -NR_cR_v wherein any (1-4C)alkyl group contained in the preceding values for R^{4h} and R^{5h} is optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy
- 15 group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein R_v is hydrogen or (1-4C)alkyl and R_c is as hereinafter defined;
- 20 R^{4h} and R^{5h} may further be independently selected from (1-4C)alkyl {optionally substituted by up to three substituents independently selected from hydroxy (excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (excluding geminal disubstitution); wherein
- 25 R_v is hydrogen or (1-4C)alkyl}; R_c is as hereinafter defined; and wherein

- 7 -

- any (1-4C)alkyl group contained in the immediately preceding optional substituents (when R^{4h} and R^{5h} are independently (1-4C)alkyl) is itself optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy,
- 5 (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein R_v is hydrogen or (1-4C)alkyl and R_c is as hereinafter defined;
- or R^{4h} is selected from one of the groups in (TAaa) to (TAac) below, or (where
- 10 appropriate) one of R^{4h} and R^{5h} is selected from the above list of R^{4h} and R^{5h} values, and the other is selected from one of the groups in (TAaa) to (TAac) below :-

(TAaa) a group of the formula (TAaa1)



(TAaa1)

- 15 wherein Z⁰ is hydrogen or (1-4C)alkyl;
 X^0 and Y^0 are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, halo, cyano, nitro, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), R_vR_wNSO₂-, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and -CONR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl]; or
- 20 one of X^0 and Y^0 is selected from the above list of X^0 and Y^0 values, and the other is selected from phenyl, phenylcarbonyl, -S(O)_q-phenyl (q is 0, 1 or 2), N-(phenyl)carbamoyl, phenylaminosulfonyl, AR₂, (AR₂)-CO-, (AR₂)-S(O)_q- (q is 0, 1 or 2), N-(AR₂)carbamoyl and (AR₂)aminosulfonyl; wherein any phenyl group in (TAaa) may be optionally substituted by up to three substituents independently selected from (1-4C)alkyl, cyano,
- 25 trifluoromethyl, nitro, halo and (1-4C)alkylsulfonyl;
- (TAab) an acetylene of the formula $\equiv\text{H}$ or $\equiv\text{-(1-4C)alkyl}$;
- (TAac) -X¹-Y¹-AR₂, -X¹-Y¹-AR_{2a}, -X¹-Y¹-AR_{2b}, -X¹-Y¹-AR₃, -X¹-Y¹-AR_{3a} or -X¹-Y¹-AR_{3b};
- wherein X¹ is a direct bond or -CH(OH)- and

- 8 -

Y^1 is $-(CH_2)_m-$, $-(CH_2)_n-NH-(CH_2)_m-$, $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$, $-C(=S)NH-(CH_2)_m-$ or $-C(=O)O-(CH_2)_m-$;

or wherein X^1 is $-(CH_2)_n-$ or $-CH(Me)-(CH_2)_m-$ and

Y^1 is $-(CH_2)_m-NH-(CH_2)_m-$, $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$, $-C(=S)NH-(CH_2)_m-$,

5 $-C(=O)O-(CH_2)_m-$ or $-S(O)_q-(CH_2)_m-$;

or wherein X^1 is $-CH_2O-$, $-CH_2NH-$ or $-CH_2N((1-4C)alkyl)-$ and

Y^1 is $-CO-(CH_2)_m-$, $-CONH-(CH_2)_m-$ or $-C(=S)NH-(CH_2)_m-$; and additionally Y^1 is

$-SO_2-$ when X^1 is $-CH_2NH-$ or $-CH_2N((1-4C)alkyl)-$, and Y^1 is $-(CH_2)_m-$ when X^1 is $-CH_2O-$ or $-CH_2N((1-4C)alkyl)-$; wherein n is 1, 2 or 3; m is 0, 1, 2 or 3 and q is 0, 1 or 2; and when Y^1

10 is $-(CH_2)_m-NH-(CH_2)_m-$ each m is independently selected from 0, 1, 2 or 3;

wherein R_c is selected from groups (R_{c1}) to (R_{c5}):-

(Rc1) (1-6C)alkyl {optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy, trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR1 defined

15 hereinafter), (1-4C)alkylS(O)_q- (q is 0, 1 or 2); or, on any but the first carbon atom of the (1-6C)alkyl chain, optionally substituted by one or more groups (including geminal

disubstitution) each independently selected from hydroxy and fluoro, and/or optionally

monosubstituted by oxo, $-NR_vR_w$ [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, \underline{N} -(1-4C)alkyl- \underline{N} -

20 (1-6C)alkanoylamino, (1-4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2));

(Rc2) $R^{13}CO-$, $R^{13}SO_2-$ or $R^{13}CS-$

wherein R^{13} is selected from (R_{c2a}) to (R_{c2e}):-

(Rc2a) AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

25 **(Rc2b)** hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, $-NR_vR_w$ [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl,

2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;


30 **(Rc2c)** (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy,

- (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)(OH)₂, and mono- and
- 5 di-(1-4C)alkoxy derivatives thereof], phosphinate [-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl,
- 10 (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-, fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q- [the (1-4C)alkyl group of (1-4C)alkylS(O)_q- being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂], and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂] and mono- and di-(1-4C)alkoxy derivatives
- 15 thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p((1-4C)alkyl)N-,
- 20 (1-4C)alkylS(O)_q-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q- and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups], CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-, AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups};
- 25 **(Rc2d)** R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is AR1, AR2, (1-4C)alkylamino (the (1-4C)alkyl group being optionally substituted by (1-4C)alkoxycarbonyl or by carboxy), benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (Rc2c)};
- (Rc2e)** R¹⁵O- wherein R¹⁵ is benzyl, (1-6C)alkyl {optionally substituted as defined for (Rc2c)}, CY1, CY2 or AR2b;
- 30 **(Rc3)** hydrogen, cyano, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-nitroethenyl,

- 10 -

2-nitro-2-((1-4C)alkyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, or of the formula **(Rc3a)**

**(Rc3a)**

wherein X^{00} is $-\text{OR}^{17}$, $-\text{SR}^{17}$, $-\text{NHR}^{17}$ and $-\text{N}(\text{R}^{17})_2$;

- 5 wherein R^{17} is hydrogen (when X^{00} is $-\text{NHR}^{17}$ and $-\text{N}(\text{R}^{17})_2$), and R^{17} is (1-4C)alkyl, phenyl or AR2 (when X^{00} is $-\text{OR}^{17}$, $-\text{SR}^{17}$ and $-\text{NHR}^{17}$); and R^{16} is cyano, nitro, (1-4C)alkylsulfonyl, (4-7C)cycloalkylsulfonyl, phenylsulfonyl, (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;
- (Rc4)** trityl, AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b;
- (Rc5)** $\text{RdOC}(\text{Re})=\text{CH}(\text{C}=\text{O})-$, $\text{RfC}(\text{C}=\text{O})\text{C}(\text{C}=\text{O})-$, $\text{RgN}=\text{C}(\text{Rh})\text{C}(\text{C}=\text{O})-$ or
- 10 $\text{RiNHC}(\text{Rj})=\text{CHC}(\text{C}=\text{O})-$ wherein Rd is (1-6C)alkyl; Re is hydrogen or (1-6C)alkyl, or Rd and Re together form a (3-4C)alkylene chain; Rf is hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, $-\text{NR}^{\text{v}}\text{R}^{\text{w}}$ [wherein R^{v} is hydrogen or (1-4C)alkyl; R^{w} is hydrogen or (1-4C)alkyl], (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-4C)alkylamino(2-6C)alkoxy, di-(1-4C)alkylamino(2-6C)alkoxy; Rg is (1-6C)alkyl,
- 15 hydroxy or (1-6C)alkoxy; Rh is hydrogen or (1-6C)alkyl; Ri is hydrogen, (1-6C)alkyl, AR1, AR2, AR2a, AR2b and Rj is hydrogen or (1-6C)alkyl;

wherein

AR1 is an optionally substituted phenyl or optionally substituted naphthyl;

- AR2** is an optionally substituted 5- or 6-membered, fully unsaturated (i.e. with the maximum
- 20 degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;
- AR2a** is a partially hydrogenated version of AR2 (i.e. AR2 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen
- 25 atom if the ring is not thereby quaternised;

AR2b is a fully hydrogenated version of AR2 (i.e. AR2 systems having no unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom;

- AR3** is an optionally substituted 8-, 9- or 10-membered, fully unsaturated (i.e. with the maximum degree of unsaturation) bicyclic heteroaryl ring containing up to four heteroatoms
- 30 independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and

- 11 -

linked via a ring carbon atom in either of the rings comprising the bicyclic system;

AR3a is a partially hydrogenated version of AR3 (i.e. AR3 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic

5 system;

AR3b is a fully hydrogenated version of AR3 (i.e. AR3 systems having no unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen atom, in either of the rings comprising the bicyclic system;

AR4 is an optionally substituted 13- or 14-membered, fully unsaturated (i.e. with the
10 maximum degree of unsaturation) tricyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and linked via a ring carbon atom in any of the rings comprising the tricyclic system;

AR4a is a partially hydrogenated version of AR4 (i.e. AR4 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen
15 atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;

CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;

CY2 is an optionally substituted cyclopentenyl or cyclohexenyl ring.

In another embodiment, the present invention provides a compound of the formula (I)
20 as hereinbefore described, or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein:

HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, containing either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on
25 a C atom, other than a C atom adjacent to the linking N atom, by an oxo or thioxo group; and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by a substituent selected from (1-4C)alkyl, (2-4C)alkenyl, (3-6C)cycloalkyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino, (1-4C)alkylthio, (1-4C)alkoxy, (1-4C)alkoxycarbonyl, halogen, cyano and trifluoromethyl and/or on an
30 available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl; or HET is an N-linked 6-membered di-hydro-heteroaryl ring containing up to three nitrogen heteroatoms in total (including the linking heteroatom), which ring is substituted on a suitable

- 12 -

C atom, other than a C atom adjacent to the linking N atom, by oxo or thioxo and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by one or two substituents independently selected from (1-4C)alkyl, (2-4C)alkenyl, (3-6C)cycloalkyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino,
 5 (1-4C)alkylthio, (1-4C)alkoxy, (1-4C)alkoxycarbonyl, halogen, cyano and trifluoromethyl and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl; and wherein at each occurrence of alkyl, alkenyl and cycloalkyl HET substituents, each is optionally substituted with one or more F, Cl or CN.

10 In this specification, HET as an N-linked 5-membered ring may be a fully or partially unsaturated heterocyclic ring, provided there is some degree of unsaturation in the ring.

Particular examples of N-linked 5-membered heteroaryl rings containing 2 to 4 heteroatoms independently selected from N, O and S (with no O-O, O-S or S-S bonds) are preferably rings containing 2 to 4 N atoms, in particular pyrazole, imidazole, 1,2,3-triazole
 15 (preferably 1,2,3-triazol-1-yl), 1,2,4-triazole (preferably 1,2,4-triazol-1-yl) and tetrazole (preferably tetrazol-2-yl).

Particular examples of N-linked 6-membered di-hydro-heteroaryl rings containing up to three nitrogen heteroatoms in total (including the linking heteroatom) include di-hydro versions of pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine and
 20 pyridine.

It is to be understood that when a value for $-X^1-$ is a two-atom link and is written, for example, as $-\text{CH}_2\text{NH}-$ it is the left hand part ($-\text{CH}_2-$ here) which is bonded to the group of formula (TAa1) to (TAa6) and the right hand part ($-\text{NH}-$ here) which is bonded to $-Y^1-$ in the definition in (TAac). Similarly, when $-Y^1-$ is a two-atom link and is written, for example, as
 25 $-\text{CONH}-$ it is the left hand part of $-Y^1-$ ($-\text{CO}-$ here) which is bonded to the right hand part of $-X^1-$, and the right hand part of $-Y^1-$ ($-\text{NH}-$ here) which is bonded to the AR2, AR2a, AR2b, AR3, AR3a or AR3b moiety in the definition in (TAac).

In this specification the term 'alkyl' includes straight chained and branched structures. For example, (1-6C)alkyl includes propyl, isopropyl and tert-butyl. However, references to
 30 individual alkyl groups such as "propyl" are specific for the straight chained version only, and references to individual branched chain alkyl groups such as "isopropyl" are specific for the

branched chain version only. A similar convention applies to other radicals, for example halo(1-4C)alkyl includes 1-bromoethyl and 2-bromoethyl.

There follow particular and suitable values for certain substituents and groups referred to in this specification. These values may be used where appropriate with any of the

5 definitions and embodiments disclosed hereinbefore, or hereinafter.

Examples of **(1-4C)alkyl** and **(1-5C)alkyl** include methyl, ethyl, propyl, isopropyl and t-butyl; examples of **(1-6C)alkyl** include methyl, ethyl, propyl, isopropyl, t-butyl, pentyl and hexyl; examples of **(1-10C)alkyl** include methyl, ethyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl and nonyl; examples of **(1-4C)alkanoylamino-(1-4C)alkyl** include

10 formamidomethyl, acetamidomethyl and acetamidoethyl; examples of **hydroxy(1-4C)alkyl** and **hydroxy(1-6C)alkyl** include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl; examples of **(1-4C)alkoxycarbonyl** include methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl; examples of **2-((1-4C)alkoxycarbonyl)ethenyl** include 2-(methoxycarbonyl)ethenyl and 2-(ethoxycarbonyl)ethenyl; examples of **2-cyano-2-**

15 **((1-4C)alkyl)ethenyl** include 2-cyano-2-methylethenyl and 2-cyano-2-ethylethenyl; examples of **2-nitro-2-((1-4C)alkyl)ethenyl** include 2-nitro-2-methylethenyl and 2-nitro-2-ethylethenyl; examples of **2-((1-4C)alkylaminocarbonyl)ethenyl** include 2-(methylaminocarbonyl)ethenyl and 2-(ethylaminocarbonyl)ethenyl; examples of **(2-4C)alkenyl** include allyl and vinyl; examples of **(2-4C)alkynyl** include ethynyl and 2-propynyl; examples of **(1-4C)alkanoyl**

20 include formyl, acetyl and propionyl; examples of **(1-4C)alkoxy** include methoxy, ethoxy and propoxy; examples of **(1-6C)alkoxy** and **(1-10C)alkoxy** include methoxy, ethoxy, propoxy and pentoxy; examples of **(1-4C)alkylthio** include methylthio and ethylthio; examples of **(1-4C)alkylamino** include methylamino, ethylamino and propylamino; examples of **di-((1-4C)alkyl)amino** include dimethylamino, N-ethyl-N-methylamino, diethylamino,

25 N-methyl-N-propylamino and dipropylamino; examples of **halo** groups include fluoro, chloro and bromo; examples of **(1-4C)alkylsulfonyl** include methylsulfonyl and ethylsulfonyl; examples of **(1-4C)alkoxy-(1-4C)alkoxy** and **(1-6C)alkoxy-(1-6C)alkoxy** include methoxymethoxy, 2-methoxyethoxy, 2-ethoxyethoxy and 3-methoxypropoxy; examples of **(1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy** include 2-(methoxymethoxy)ethoxy,

30 2-(2-methoxyethoxy)ethoxy; 3-(2-methoxyethoxy)propoxy and 2-(2-ethoxyethoxy)ethoxy; examples of **(1-4C)alkylS(O)₂amino** include methylsulfonylamino and ethylsulfonylamino; examples of **(1-4C)alkanoylamino** and **(1-6C)alkanoylamino** include formamido, acetamido

- 14 -

and propionylamino; examples of **(1-4C)alkoxycarbonylamino** include methoxycarbonylamino and ethoxycarbonylamino; examples of **N-(1-4C)alkyl-N-(1-6C)alkanoylamino** include N-methylacetamido, N-ethylacetamido and N-methylpropionamido; examples of **(1-4C)alkylthiocarbonylamino** include MeS-C(=O)-N-
5 and EtS-C(=O)-N-; examples of **(1-4C)alkylS(O)_pNH-** wherein p is 1 or 2 include methylsulfinylamino, methylsulfonylamino, ethylsulfinylamino and ethylsulfonylamino; examples of **(1-4C)alkylS(O)_p((1-4C)alkyl)N-** wherein p is 1 or 2 include methylsulfinylmethylamino, methylsulfonylmethylamino, 2-(ethylsulfinyl)ethylamino and 2-(ethylsulfonyl)ethylamino; examples of **fluoro(1-4C)alkylS(O)_pNH-** wherein p is 1 or 2
10 include trifluoromethylsulfinylamino and trifluoromethylsulfonylamino; examples of **fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)NH-** wherein p is 1 or 2 include trifluoromethylsulfinylmethylamino and trifluoromethylsulfonylmethylamino; examples of **(1-4C)alkoxy(hydroxy)phosphoryl** include methoxy(hydroxy)phosphoryl and ethoxy(hydroxy)phosphoryl; examples of **di-(1-4C)alkoxyphosphoryl** include di-
15 methoxyphosphoryl, di-ethoxyphosphoryl and ethoxy(methoxy)phosphoryl; examples of **(1-4C)alkylS(O)_q-** wherein q is 0, 1 or 2 include methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl and ethylsulfonyl; examples of **phenylS(O)_q** and **naphthylS(O)_q-** wherein q is 0, 1 or 2 are phenylthio, phenylsulfinyl, phenylsulfonyl and naphthylthio, naphthylsulfinyl and naphthylsulfonyl respectively; examples of **benzyloxy-**
20 **(1-4C)alkyl** include benzyloxymethyl and benzyloxyethyl; examples of a **(3-4C)alkylene** chain are trimethylene or tetramethylene; examples of **(1-6C)alkoxy-(1-6C)alkyl** include methoxymethyl, ethoxymethyl and 2-methoxyethyl; examples of **hydroxy-(2-6C)alkoxy** include 2-hydroxyethoxy and 3-hydroxypropoxy; examples of **(1-4C)alkylamino-(2-6C)alkoxy** include 2-methylaminoethoxy and 2-ethylaminoethoxy; examples of
25 **di-(1-4C)alkylamino-(2-6C)alkoxy** include 2-dimethylaminoethoxy and 2-diethylaminoethoxy; examples of **phenyl(1-4C)alkyl** include benzyl and phenethyl; examples of **(1-4C)alkylcarbamoyl** include methylcarbamoyl and ethylcarbamoyl; examples of **di((1-4C)alkyl)carbamoyl** include di(methyl)carbamoyl and di(ethyl)carbamoyl; examples of **hydroxyimino(1-4C)alkyl** include hydroxyiminomethyl, 2-(hydroxyimino)ethyl and
30 1-(hydroxyimino)ethyl; examples of **(1-4C)alkoxyimino-(1-4C)alkyl** include methoxyiminomethyl, ethoxyiminomethyl, 1-(methoxyimino)ethyl and

- 15 -

2-(methoxyimino)ethyl; examples of **halo(1-4C)alkyl** include, halomethyl, 1-haloethyl, 2-haloethyl, and 3-halopropyl; examples of **nitro(1-4C)alkyl** include nitromethyl, 1-nitroethyl, 2-nitroethyl and 3-nitropropyl; examples of **amino(1-4C)alkyl** include aminomethyl, 1-aminoethyl, 2-aminoethyl and 3-aminopropyl; examples of **cyano(1-4C)alkyl** include cyanomethyl, 1-cyanoethyl, 2-cyanoethyl and 3-cyanopropyl; examples of **(1-4C)alkanesulfonamido** include methanesulfonamido and ethanesulfonamido; examples of **(1-4C)alkylaminosulfonyl** include methylaminosulfonyl and ethylaminosulfonyl; and examples of **di-(1-4C)alkylaminosulfonyl** include dimethylaminosulfonyl, diethylaminosulfonyl and N-methyl-N-ethylaminosulfonyl; examples of **(1-4C)alkanesulfonyloxy** include methylsulfonyloxy, ethylsulfonyloxy and propylsulfonyloxy; examples of **(1-4C)alkanoyloxy** include acetoxy; examples of **(1-4C)alkylaminocarbonyl** include methylaminocarbonyl and ethylaminocarbonyl; examples of **di((1-4C)alkyl)aminocarbonyl** include dimethylaminocarbonyl and diethylaminocarbonyl; examples of **(3-6C)cycloalkyl** and **(3-8C)cycloalkyl** include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; examples of **(4-7C)cycloalkyl** include cyclobutyl, cyclopentyl and cyclohexyl; examples of **(3-6C)cycloalkenyl** include cyclopentenyl and cyclohexenyl; examples of **di(N-(1-4C)alkyl)aminomethylimino** include dimethylaminomethylimino and diethylaminomethylimino.

Particular values for AR2 include, for example, for those AR2 containing one heteroatom, furan, pyrrole, thiophene; for those AR2 containing one to four N atoms, pyrazole, imidazole, pyridine, pyrimidine, pyrazine, pyridazine, 1,2,3- & 1,2,4-triazole and tetrazole; for those AR2 containing one N and one O atom, oxazole, isoxazole and oxazine; for those AR2 containing one N and one S atom, thiazole and isothiazole; for those AR2 containing two N atoms and one S atom, 1,2,4- and 1,3,4-thiadiazole.

Particular examples of AR2a include, for example, dihydropyrrole (especially 2,5-dihydropyrrol-4-yl) and tetrahydropyridine (especially 1,2,5,6-tetrahydropyrid-4-yl).

Particular examples of AR2b include, for example, tetrahydrofuran, pyrrolidine, morpholine (preferably morpholino), thiomorpholine (preferably thiomorpholino), piperazine (preferably piperazino), imidazoline and piperidine, 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl and 1,4-dioxan-2-yl.

Particular values for AR3 include, for example, bicyclic benzo-fused systems containing a 5- or 6-membered heteroaryl ring containing one nitrogen atom and optionally

- 16 -

1-3 further heteroatoms chosen from oxygen, sulfur and nitrogen. Specific examples of such ring systems include, for example, indole, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzisothiazole, benzoxazole, benzisoxazole, quinoline, quinoxaline, quinoxaline, phthalazine and cinnoline.

- 5 Other particular examples of AR3 include 5/5-, 5/6 and 6/6 bicyclic ring systems containing heteroatoms in both of the rings. Specific examples of such ring systems include, for example, purine and naphthyridine.

Further particular examples of AR3 include bicyclic heteroaryl ring systems with at least one bridgehead nitrogen and optionally a further 1-3 heteroatoms chosen from oxygen,
 10 sulfur and nitrogen. Specific examples of such ring systems include, for example, 3H-pyrrolo[1,2-a]pyrrole, pyrrolo[2,1-b]thiazole, 1H-imidazo[1,2-a]pyrrole, 1H-imidazo[1,2-a]imidazole, 1H,3H-pyrrolo[1,2-c]oxazole, 1H-imidazo[1,5-a]pyrrole, pyrrolo[1,2-b]isoxazole, imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, indolizine, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine,
 15 pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrazine, pyrrolo[1,2-a]pyrimidine, pyrido[2,1-c]-s-triazole, s-triazole[1,5-a]pyridine, imidazo[1,2-c]pyrimidine, imidazo[1,2-a]pyrazine, imidazo[1,2-a]pyrimidine, imidazo[1,5-a]pyrazine, imidazo[1,5-a]pyrimidine, imidazo[1,2-b]-pyridazine, s-triazolo[4,3-a]pyrimidine, imidazo[5,1-b]oxazole and imidazo[2,1-b]oxazole. Other
 20 specific examples of such ring systems include, for example, [1H]-pyrrolo[2,1-c]oxazine, [3H]-oxazolo[3,4-a]pyridine, [6H]-pyrrolo[2,1-c]oxazine and pyrido[2,1-c][1,4]oxazine. Other specific examples of 5/5- bicyclic ring systems are imidazooxazole or imidazothiazole, in particular imidazo[5,1-b]thiazole, imidazo[2,1-b]thiazole, imidazo[5,1-b]oxazole or imidazo[2,1-b]oxazole.

- 25 Particular examples of AR3a and AR3b include, for example, indoline, 1,3,4,6,9,9a-hexahydropyrido[2,1c][1,4]oxazin-8-yl, 1,2,3,5,8,8a-hexahydroimidazo[1,5a]pyridin-7-yl, 1,5,8,8a-tetrahydrooxazolo[3,4a]pyridin-7-yl, 1,5,6,7,8,8a-hexahydrooxazolo[3,4a]pyridin-7-yl, (7aS)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, (7aS)[5H]-1,2,3,7a-tetrahydropyrrolo[1,2c]imidazol-6-yl,
 30 (7aR)[3H,5H]-1,7a-dihydropyrrolo[1,2c]oxazol-6-yl, [3H,5H]-pyrrolo[1,2-c]oxazol-6-yl, [5H]-2,3-dihydropyrrolo[1,2-c]imidazol-6-yl, [3H,5H]-pyrrolo[1,2-c]thiazol-6-yl, [3H,5H]-1,7a-dihydropyrrolo[1,2-c]thiazol-6-yl, [5H]-pyrrolo[1,2-c]imidazol-6-yl,

- 17 -

[1H]-3,4,8,8a-tetrahydropyrrolo[2,1-c]oxazin-7-yl, [3H]-1,5,8,8a-tetrahydrooxazolo[3,4-a]pyrid-7-yl, [3H]-5,8-dihydrooxazolo[3,4-a]pyrid-7-yl and 5,8-dihydroimidazo[1,5-a]pyrid-7-yl.

Particular values for AR4 include, for example, pyrrolo[a]quinoline,
 5 2,3-pyrroloisoquinoline, pyrrolo[a]isoquinoline, 1H-pyrrolo[1,2-a]benzimidazole, 9H-imidazo[1,2-a]indole, 5H-imidazo[2,1-a]isoindole, 1H-imidazo[3,4-a]indole, imidazo[1,2-a]quinoline, imidazo[2,1-a]isoquinoline, imidazo[1,5-a]quinoline and imidazo[5,1-a]isoquinoline.

The nomenclature used is that found in, for example, "Heterocyclic Compounds
 10 (Systems with bridgehead nitrogen), W.L.Mosby (Interscience Publishers Inc., New York), 1961, Parts 1 and 2.

Where optional substituents are listed such substitution is preferably not geminal disubstitution unless stated otherwise. If not stated elsewhere suitable optional substituents for a particular group are those as stated for similar groups herein.

15 Suitable substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are (on an available carbon atom) up to three substituents independently selected from (1-4C)alkyl {optionally substituted by (preferably one) substituents selected independently from hydroxy, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) (this last substituent preferably on AR1 only), (1-4C)alkoxy, (1-4C)alkoxycarbonyl, cyano, nitro,
 20 (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w}, trifluoromethyl, hydroxy, halo, nitro, cyano, thiol, (1-4C)alkoxy, (1-4C)alkanoyloxy, dimethylaminomethyleneaminocarbonyl, di(N-(1-4C)alkyl)aminomethylimino, carboxy, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, (1-4C)alkylSO₂amino, (2-4C)alkenyl {optionally substituted by carboxy or (1-4C)alkoxycarbonyl}, (2-4C)alkynyl, (1-4C)alkanoylamino, oxo (=O), thioxo (=S),
 25 (1-4C)alkanoylamino {the (1-4C)alkanoyl group being optionally substituted by hydroxy}, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2) {the (1-4C)alkyl group being optionally substituted by one or more groups independently selected from cyano, hydroxy and (1-4C)alkoxy}, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl].

30 Further suitable substituents on AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 (on an available carbon atom), and also on alkyl groups (unless indicated otherwise) are up to three substituents independently selected from

trifluoromethoxy, benzoylamino, benzoyl, phenyl {optionally substituted by up to three substituents independently selected from halo, (1-4C)alkoxy or cyano}, furan, pyrrole, pyrazole, imidazole, triazole, pyrimidine, pyridazine, pyridine, isoxazole, oxazole, isothiazole, thiazole, thiophene, hydroxyimino(1-4C)alkyl, (1-4C)alkoxyimino(1-4C)alkyl, halo-
 5 (1-4C)alkyl, (1-4C)alkanesulfonamido, -SO₂NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl].

Preferable optional substituents on Ar2b as 1,3-dioxolan-4-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl or 1,4-dioxan-2-yl are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), (1-4C)alkoxy, (1-4C)alkylthio,
 10 acetamido, (1-4C)alkanoyl, cyano, trifluoromethyl and phenyl].

Preferable optional substituents on CY1 & CY2 are mono- or disubstitution by substituents independently selected from (1-4C)alkyl (including geminal disubstitution), hydroxy, (1-4C)alkoxy, (1-4C)alkylthio, acetamido, (1-4C)alkanoyl, cyano, and trifluoromethyl.

15 Suitable substituents on AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4 and AR4a are (on an available nitrogen atom, where such substitution does not result in quaternization) (1-4C)alkyl, (1-4C)alkanoyl {wherein the (1-4C)alkyl and (1-4C)alkanoyl groups are optionally substituted by (preferably one) substituents independently selected from cyano, hydroxy, nitro, trifluoromethyl, (1-4C)alkyl S(O)_q- (q is 0, 1 or 2), (1-4C)alkoxy,
 20 (1-4C)alkoxycarbonyl, (1-4C)alkanoylamino, -CONR_vR_w or -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl]}, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxycarbonyl or oxo (to form an N-oxide).

Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably)
 25 hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, N-methyl d-glucamine and amino acids
 30 such as lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). A
5 prodrug may be used to alter or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains a suitable group or substituent which can be derivatised to form a prodrug. Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof.

10 Various forms of prodrugs are known in the art, for examples see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191
15 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

An in-vivo hydrolysable ester of a compound of the formula (I) or a pharmaceutically-
20 acceptable salt thereof containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.

Suitable pharmaceutically-acceptable esters for carboxy include (1-6C)alkoxymethyl esters for example methoxymethyl, (1-6C)alkanoyloxymethyl esters for example
25 pivaloyloxymethyl, phthalidyl esters, (3-8C)cycloalkoxycarbonyloxy(1-6C)alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-onylmethyl esters for example 5-methyl-1,3-dioxolan-2-ylmethyl; and (1-6C)alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

30 An in-vivo hydrolysable ester of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof containing a hydroxy group or groups includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and

- 20 -


related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include (1-10C)alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and

5 phenylacetyl, (1-10C)alkoxycarbonyl (to give alkyl carbonate esters), di-(1-4C)alkylcarbamoyl and N-(di-(1-4C)alkylaminoethyl)-N-(1-4C)alkylcarbamoyl (to give carbamates), di-(1-4C)alkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl and phenylacetyl include chloromethyl or aminomethyl, (1-4C)alkylaminomethyl and di-((1-4C)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom

10 via a methylene linking group to the 3- or 4-position of the benzoyl ring.

Certain suitable in-vivo hydrolysable esters of a compound of the formula (I) are described within the definitions listed in this specification, for example esters described by the definition (Rc2d), and some groups within (Rc2c). Suitable in-vivo hydrolysable esters of a compound of the formula (I) are described as follows. For example, a 1,2-diol may be

15 cyclised to form a cyclic ester of formula (PD1) or a pyrophosphate of formula (PD2) :




Particularly interesting are such cyclised pro-drugs when the 1,2-diol is on a (1-4C)alkyl chain linked to a carbonyl group in a substituent of formula Rc borne by a

20 nitrogen atom in (TC4). Esters of compounds of formula (I) wherein the HO- function/s in (PD1) and (PD2) are protected by (1-4C)alkyl, phenyl or benzyl are useful intermediates for the preparation of such pro-drugs.

Further in-vivo hydrolysable esters include phosphoramidic esters, and also compounds of formula (I) in which any free hydroxy group independently forms a phosphoryl

25 (npd is 1) or phosphiryl (npd is 0) ester of the formula (PD3)), wherein npd is independently 0 or 1 for each oxo group :

- 21 -



For the avoidance of doubt, phosphono is $-\text{P}(\text{O})(\text{OH})_2$; (1-4C)alkoxy(hydroxy)-phosphoryl is a mono-(1-4C)alkoxy derivative of $-\text{O}-\text{P}(\text{O})(\text{OH})_2$; and di-(1-4C)alkoxyphosphoryl is a di-(1-4C)alkoxy derivative of $-\text{O}-\text{P}(\text{O})(\text{OH})_2$.

5 Useful intermediates for the preparation of such esters include compounds containing a group/s of formula (PD3) in which either or both of the $-\text{OH}$ groups in (PD3) is independently protected by (1-4C)alkyl (such compounds also being interesting compounds in their own right), phenyl or phenyl-(1-4C)alkyl (such phenyl groups being optionally substituted by 1 or 2 groups independently selected from (1-4C)alkyl, nitro, halo and

10 (1-4C)alkoxy).

Thus, prodrugs containing groups such as (PD1), (PD2) and (PD3) may be prepared by reaction of a compound of formula (I) containing suitable hydroxy group/s with a suitably protected phosphorylating agent (for example, containing a chloro or dialkylamino leaving group), followed by oxidation (if necessary) and deprotection. Prodrugs containing a group

15 such as (PS1) may be obtained by analagous chemistry.

When a compound of formula (I) contains a number of free hydroxy group, those groups not being converted into a prodrug functionality may be protected (for example, using a t-butyl-dimethylsilyl group), and later deprotected. Also, enzymatic methods may be used to selectively phosphorylate or dephosphorylate alcohol functionalities.

20 Other interesting in-vivo hydrolysable esters include, for example, those in which R_c is defined by, for example, $\text{R}^{14}\text{C}(\text{O})\text{O}(1-6\text{C})\text{alkyl}-\text{CO}-$ (wherein R^{14} is for example, benzyloxy-(1-4C)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(1-4C)piperazino-(1-4C)alkyl, piperazino-(1-4C)alkyl and morpholino-(1-4C)alkyl.


25 Where pharmaceutically-acceptable salts of an in-vivo hydrolysable ester may be formed this is achieved by conventional techniques. Thus, for example, compounds containing a group of formula (PD1), (PD2) and/or (PD3) may ionise (partially or fully) to form salts with an appropriate number of counter-ions. Thus, by way of example, if an in-vivo hydrolysable ester prodrug of a compound of formula (I) contains two (PD3) groups, there are

30 four $\text{HO}-\text{P}-$ functionalities present in the overall molecule, each of which may form an

- 22 -

appropriate salt (i.e. the overall molecule may form, for example, a mono-, di-, tri- or tetra-sodium salt).

The compounds of the present invention have a chiral centre at the C-5 position of the isoxazoline ring. The pharmaceutically active enantiomer is of the formula (IA):



The present invention includes the pure enantiomer depicted above or mixtures of the 5R and 5S enantiomers, for example a racemic mixture. If a mixture of enantiomers is used, a larger amount (depending upon the ratio of the enantiomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer. For example, the enantiomer depicted above is the 5(R) isomer when HET is 1,2,3- or 1,2,4-triazole or tetrazole.

Furthermore, some compounds of the formula (I) may have other chiral centres. It is to be understood that the invention encompasses all such optical and diastereo-isomers, and racemic mixtures, that possess antibacterial activity. It is well known in the art how to prepare optically-active forms (for example by resolution of the racemic form by recrystallisation techniques, by chiral synthesis, by enzymatic resolution, by biotransformation or by chromatographic separation) and how to determine antibacterial activity as described hereinafter.

Furthermore, some compounds of the formula (I) may exist as cis- and trans- isomers. It is to be understood that the invention encompasses all such isomers, and mixtures thereof, that possess antibacterial activity.

The invention relates to all tautomeric forms of the compounds of the formula (I) that possess antibacterial activity.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess antibacterial

activity.

It is also to be understood that certain compounds of the formula (I) may exhibit polymorphism, and that the invention encompasses all such forms which possess antibacterial activity.

5 As stated before, we have discovered a range of compounds that have good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram negative pathogens such as *H.influenzae* & *M.catarrhalis*. They have good physical and/or pharmacokinetic properties in general, and favourable toxicological profiles.

10 Particularly preferred compounds of the invention comprise a compound of formula (I), or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, wherein the substituents Q, HET, T and other substituents mentioned above have values disclosed hereinbefore, or any of the following values (which may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore or hereinafter):

15 In one embodiment of the invention are provided compounds of formula (I), or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, in which Q, HET, T and other substituents mentioned above have the values disclosed hereinbefore and Rs is selected from the group (Rsb).

In one embodiment is provided a compound of formula (I) as defined herein wherein
20 Q is selected from Q1 to Q9. In another embodiment is provided a compound of formula (I) as defined herein wherein Q is Q10.

Preferably Q is selected from Q1, Q2, Q4, Q6 and Q9; especially Q1, Q2 and Q9; more particularly Q1 and Q2; and most preferably Q is Q1.

In one embodiment T is an optionally substituted C-linked (fully unsaturated)
25 5-membered heteroaryl ring system containing 1, 2 or 3 heteroatoms drawn in combination from O, N, or S, optionally substituted, in a position not adjacent to the linking position, by one or more substituents independently selected from R^{4h}, R^{5h} and 6th defined herein.

In another embodiment T is selected from the groups of formula (TAa1) to (TAa6) defined herein.

30 Preferably T is selected from (TAa1 to TAa3). Especially preferred is each of these values of T when present in Q1 and Q2, particularly in Q1.

In one embodiment Rs has values (Rsa) to (Rsc1 -3).

- 24 -

In another embodiment Rs has values (Rsd).

Preferable Rs groups are those of (Rsa) and (Rsb).


In one aspect, suitable values of (Rsa) are halo, amino and (2-4C)cycloalkenyl.

In another aspect a suitable value of (Rsd) is cyano.

5 In (Rsb) the substituted (1-4C)alkyl group is preferably a substituted methyl group.

In one aspect, suitable values for a substituent on a (1-4C)alkyl group in (Rsb) are cyano, azido, halo and (1-4C)alkyl-S(O)_q- wherein q=0, particularly wherein the (1-4C)alkyl group is a methyl group.

In (Rsb), when the (1-4C)alkyl group is substituted by a N-linked 5-membered
 10 heteroaryl ring it will be appreciated that the ring is aromatic and that when the ring is optionally substituted on an available carbon atom by oxo or thioxo then, when HET contains 1 to 3 further nitrogen heteroatoms, one of the further nitrogen heteroatoms is present as NH or as N-(1-4C)alkyl. Similarly, when the ring is optionally substituted on an available nitrogen atom by (1-4C)alkyl then the ring is substituted on an available carbon atom by oxo
 15 or thioxo. Preferred values for the N-linked 5-membered heteroaryl ring as a substituent in (Rsb) are the following rings (HET-P1 to HET-P5) :-



20 In (Rsc1) to (Rsc3), particular rings are morpholino, tetrahydropyridyl and dihydropyrrolyl.

Preferable (Rs) groups provided by optional F and/or Cl and/or Br and/or one cyano further substituents in (Rsa) and (Rsb) are, for example, Rs as trifluoromethyl, -CHF₂, -CH₂F, -CH₂Cl -CH₂Br, -CH₂CN, -CF₂NH(1-4C)alkyl, -CF₂CH₂OH, -CH₂OCF₃, -CH₂OCHF₂,
 25 -CH₂OCH₂F, -NHCF₂CH₃.

In another embodiment, T is selected from TAa1 and TAa2. In a further embodiment, T is TAa1.

Preferably R^{6h} is hydrogen or (1-4C)alkyl, and R^{4h} and R^{5h} are independently selected from hydrogen, cyano, (1-4C)alkoxycarbonyl, -CONR^vR^w, hydroxy(1-4C)alkyl,

- 25 -

NRvRw(1-4C)alkyl, -NRcRv(1-4C)alkyl; wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl}; Rc is as hereinbefore defined.

More preferably, R^{5h} and R^{6h} are hydrogen and R^{4h} is selected from cyano, (1-4C)alkoxycarbonyl, -CONRcRv (preferably with Rc as hydrogen or (1-4C)alkyl), hydroxy-
 5 (1-4C)alkyl and -NRcRv(1-4C)alkyl; wherein Rv is hydrogen or (1-4C)alkyl and Rc is preferably (Rc2) as hereinbefore defined (especially wherein R¹³ is (Rc2c) as hereinbefore defined).

When R^{4h} and R^{5h} are independently selected from optionally substituted (as defined) (1-4C)alkyl, preferably there are one or two substituents, most especially just one
 10 substituent; and when the optional substituent is -CONRcRv or -NRcRv, Rc is preferably hydrogen, (1-4C)alkyl or (1-4C)alkanoyl.

The above preferred values of (TAa) are particularly preferred when present in Q1 or Q2, especially Q1. Most preferable is (TAa1) with preferable R^{4h} substituents as hereinbefore defined.

15 Preferable values for other substituents (which may be used where appropriate with any of the definitions and embodiments disclosed hereinbefore or hereinafter) are :-

- (a) In one embodiment HET is a 6-membered heteroaryl as defined herein, and in another embodiment HET is a 5-membered heteroaryl as defined herein.
- (b) When HET is a 5-membered heteroaryl as defined herein, preferably HET is 1,2,3-
 20 triazole (especially 1,2,3-triazol-1-yl), 1,2,4-triazole (especially 1,2,4-triazol-1-yl) and tetrazole (preferably tetrazol-2-yl).
- (c) When HET is a 6-membered heteroaryl as defined herein, preferably HET is a dihydro version of pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine and pyridine.
- 25 (d) In one aspect, preferably HET is unsubstituted. In another aspect HET is substituted as described in any embodiment or aspect described herein.
- (e) In one aspect preferably one of R² and R³ is hydrogen and the other fluoro. In another aspect both R² and R³ are fluoro.
- (f) Preferably Rc is R¹³CO- and preferably R¹³ is (1-4C)alkoxycarbonyl,
 30 hydroxy(1-4C)alkyl, (1-4C)alkyl (optionally substituted by one or two hydroxy groups, or by an (1-4C)alkanoyl group), (1-4C)alkylamino, dimethylamino(1-4C)alkyl, (1-4C)alkoxymethyl, (1-4C)alkanoylmethyl, (1-4C)alkanoyloxy(1-4C)alkyl, (1-5C)alkoxy or

- 26 -

2-cyanoethyl.

(g) More preferably R^{13} is 1,2-dihydroxyethyl, 1,3-dihydroxyprop-2-yl, 1,2,3-trihydroxyprop-1-yl, methoxycarbonyl, hydroxymethyl, methyl, methylamino, dimethylaminomethyl, methoxymethyl, acetoxymethyl, methoxy, methylthio, naphthyl,

5 tert-butoxy or 2-cyanoethyl.

(h) Particularly preferred as R^{13} is 1,2-dihydroxyethyl, 1,3-dihydroxyprop-2-yl or 1,2,3-trihydroxyprop-1-yl.


(i) In another aspect preferably R^{13} is hydrogen, (1-10C)alkyl [optionally substituted by one or more hydroxy] or $R^{14}C(O)O(1-6C)$ alkyl.

10 For compounds of formula (I) preferred values for R_c are those in group (Rc2) when present in any of the definitions herein containing R_c .

In the definition of (Rc2c) the AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups are preferably excluded.

Especially preferred compounds of the present invention are of the formula (IB):

15



20

(IB)

wherein HET is 1,2,3-triazole (especially 1,2,3-triazol-1-yl), 1,2,4-triazole (especially 1,2,4-triazol-1-yl) and tetrazole (preferably tetrazol-2-yl) or HET is a di-hydro version of pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine and pyridine; R^2 and R^3 are independently hydrogen or fluoro; and

25 T is selected from (TAa1 to TAa6), or in-vivo hydrolysable esters or pharmaceutically-acceptable salts thereof.

Further especially preferred compounds of the invention are of the formula (IB) wherein HET is 1,2,3-triazole (especially 1,2,3-triazol-1-yl), 1,2,4-triazole (especially 1,2,4-triazol-1-yl) or tetrazole (preferably tetrazol-2-yl;

30 R^2 and R^3 are independently hydrogen or fluoro;

T is selected from (TAa1 & 2), or in-vivo hydrolysable esters or pharmaceutically-acceptable salts thereof.

- 27 -

In the above aspects and preferred compounds of formula (IB), in (TAa1 to TAa6), preferably R^{5h} and R^{6h} are hydrogen and R^{4h} is selected from cyano, (1-4C)alkoxycarbonyl, -CONRcRv (preferably with Rc as hydrogen or (1-4C)alkyl), hydroxy-(1-4C)alkyl and -NRcRv(1-4C)alkyl; wherein Rv is hydrogen or (1-4C)alkyl and Rc is as defined in (Rc2) and especially $R^{13}CO-$ wherein R^{13} is preferably (1-4C)alkoxycarbonyl, hydroxy(1-4C)alkyl, (1-4C)alkyl (optionally substituted by one or two hydroxy groups, or by an (1-4C)alkanoyl group), (1-4C)alkylamino, dimethylamino(1-4C)alkyl, (1-4C)alkoxymethyl, (1-4C)alkanoylmethyl, (1-4C)alkanoyloxy(1-4C)alkyl, (1-5C)alkoxy or 2-cyanoethyl).

In the above aspects and preferred compounds of formula (IB), preferable optional substituents Rs on HET are fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, bromomethyl, cyanomethyl, cyano, amino, azido, alkylthioalkyl such as methylthiomethyl, or 2-propynyl.

In all of the above aspects and preferred compounds of formula (IB), in-vivo hydrolysable esters are preferred where appropriate, especially phosphoryl esters (as defined by formula (PD3) with npd as 1).

In all of the above definitions the preferred compounds are as shown in formula (IA).

Particular compounds of the present invention include the following Examples, in particular Examples No. 1, and No. 3 and the individual (5R) isomers thereof.

20 Process section :

In a further aspect the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof. It will be appreciated that during certain of the following processes certain substituents may require protection to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.

For examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: John Wiley & Sons).

30 Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group

with minimum disturbance of groups elsewhere in the molecule.

Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

Resins may also be used as a protecting group.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

A compound of the formula (I), or a pharmaceutically-acceptable salt or an in-vivo
5 hydrolysable ester thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a compound of the formula (I), or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated by the following representative examples. Necessary starting materials may be obtained by standard
10 procedures of organic chemistry (see, for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March). The preparation of such starting materials is described within the accompanying non-limiting Examples (in which, for example, 3,5-difluorophenyl, 3-fluorophenyl and (des-fluoro)phenyl containing intermediates may all be prepared by analogous procedures; or by alternative procedures - for example, the preparation of
15 (T group)-(fluoro)phenyl intermediates by reaction of a (fluoro)phenylstannane with, for example, a pyran or (tetrahydro)pyridine compound, may also be prepared by anion chemistry (see, for example, WO97/30995).

Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist. Information on the
20 preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the following Patent and Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference : WO99/02525; WO98/54161; WO97/37980; WO97/30981 (& US5,736,545); WO97/21708 (& US5,719,154); WO97/10223; WO97/09328; WO96/35691;
25 WO96/23788; WO96/15130; WO96/13502; WO95/25106 (& US5,668,286); WO95/14684 (& US5,652,238); WO95/07271 (& US5,688,792); WO94/13649; WO94/01110; WO93/23384 (& US5,547,950 & US 5,700,799); WO93/09103 (& US5,565,571, US5,654,428, US5,654,435, US5,756,732 & US5,801,246); US5,231,188; US5,247,090; US5,523,403; WO97/27188; WO97/30995; WO97/31917; WO98/01447; WO98/01446;
30 WO99/10342; WO99/10343; WO99/11642; WO99/64416; WO99/64417 and GB99/03299; European Patent Application Nos. 0,359,418 and 0,609,905; 0,693,491 A1 (& US5,698,574); 0,694,543 A1 (& AU 24985/95); 0,694,544 A1 (& CA 2,154,024); 0,697,412 A1 (&

- 30 -

US5,529,998); 0,738,726 A1 (& AU 50735/96); 0,785,201 A1 (& AU 10123/97); German Patent Application Nos. DE 195 14 313 A1 (& US5,529,998); DE 196 01 264 A1 (& AU 10098/97); DE 196 01 265 A1 (& AU 10097/97); DE 196 04 223 A1 (& AU 12516/97); DE 196 49 095 A1 (& AU 12517/97).

5 The following Patent and Application Publications may also provide useful information and the contents of the relevant process sections are hereby incorporated herein by reference : FR 2458547; FR 2500450(& GB 2094299, GB 2141716 & US 4,476,136); DE 2923295 (& GB 2028306, GB 2054575, US4,287,351, US4,348,393, US4,413,001, US4,435,415 & US4,526,786), DE 3017499 (& GB 2053196, US4,346,102 & US4,372,967);
10 US4,705,799; European Patent Application Nos. 0,312,000; 0,127,902; 0,184,170; 0,352,781; 0,316,594.

The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references to obtain necessary starting materials.


Thus, the present invention also provides that the compounds of the formulae (I) and
15 pharmaceutically-acceptable salts and in-vivo hydrolysable esters thereof, can be prepared by a process (a) to (i) as follows (wherein the variables are as defined hereinbefore or after unless otherwise stated) :

(a) by modifying a substituent in or introducing a substituent into another compound of formula (I); such changes may be usefully made in many positions of compounds of formula
20 (I), for instance a heterocyclyl group linked through nitrogen (optionally substituted on a carbon other than a carbon atom adjacent to the linking nitrogen ring atom) may be converted into another heterocyclyl group linked through nitrogen (optionally substituted on a carbon other than a carbon atom adjacent to the linking nitrogen ring atom) by introduction of a new ring substituent or by refunctionalisation of an existing ring substituent, for instance by
25 modifying the 4-substituent of a 4-substituted 1,2,3-triazol-1-yl group; or for instance such changes may be usefully made in the group Q; for example an alkylthio group may be oxidised to an alkylsulfinyl or alkylsulfonyl group, for instance a group R^{4h} that contains an alkylthio group may be oxidized to an alkylsulfinyl or alkylsulfonyl group or for example a group R^{4h} that contains an amino group may be converted into its acylamino derivative in the
30 last step of the preparation of a compound of the formula (I);

or

(b) by reaction of a compound of formula (II) :

- 31 -



(II)

wherein Y is a displaceable group (which may be (i) generated in-situ, for example under Mitsunobu conditions, or (ii) preformed, such as chloro or mesylate) with a compound of the
 5 formula (III) :

HET

(III)

wherein HET is HET-H free-base form or HET⁻ anion formed from the free base form; or


(c) by reaction of a compound of the formula (IV) :

10

Q-Z

(IV)

wherein Z is an isocyanate, amine or urethane group with an epoxide of the formula (V):




(V)

15

or

(d) by reaction of a compound of formula (VI) :



(VI)

20 wherein Y' is a group HET as hereinabove defined, X is a replaceable substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue - located at a position substituted by T in any of the aromatic embodiments Q1 - Q8 of Qn as hereinabove defined for Q, but with X in place of the substituent T, with a compound of the formula (VII) :


- 32 -

T-X'

(VII)


wherein T-X' is a five-membered heterocycle with 1-3 heteroatoms drawn in combination from O, N, and S and X' is a replaceable C-linked substituent - such as chloride, bromide, iodide, trifluoromethylsulfonyloxy, trimethylstannyl, trialkoxysilyl, or a boronic acid residue; wherein the substituents X and X' are chosen to be complementary pairs of substituents known in the art to be suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0); or

(e) by reaction of a compound of formula (VIII):



(VIII)

wherein Y' is a group HET as defined herein above and X1 and X2 here are independently optionally substituted heteroatoms drawn in combination from O, N, and S such that C(X1)X2 constitutes a substituent that is a carboxylic acid derivative substituent located at a position substituted by T in any of the aromatic embodiments Q1 – Q10 of Qn as hereinabove defined for Q with a compound of the formula (IX) and X3 and X4 are independently optionally substituted heteroatoms drawn in combination from O, N, and S:




(IX)

and wherein one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted hydrazide, thiohydrazide, or amidrazone, and the other one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted acylating, thioacylating, or imidoylating agent such that C(X1)X2 and C(X3)X4 may be condensed together to form a 5-membered heterocycle containing 3 heteroatoms drawn in combination from O, N, and S, for instance thiadiazole, by methods well-known in the art; or


(f) by reaction of a compound of formula (X):

- 33 -



(X)

wherein Y' is a group HET as defined herein above and C(X5)X6 constitutes a substituent located at a position substituted by T in any of the aromatic embodiments Q1 – Q8 of Qn as
 5 hereinabove defined for Q with a compound of the formula (XI):



(XI)

- wherein one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted alpha-(leaving-group-substituted)ketone, wherein the leaving group is for example a halo-group or an (alkyl
 10 or aryl)-sulfonyloxy-group, and the other one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted amide, thioamide, or amidine, such that C(X5)X6 and C(X7)X8 are groups that may be condensed together to form a 5-membered heterocycle containing 2 heteroatoms drawn in combination from O, N, and S, for instance thiazole, by methods well-known in the art; or
- 15 (g) for HET as optionally substituted 1,2,3-triazoles, compounds of the formula (I) may be made by cycloaddition via the azide (wherein e.g. Y in (II) is azide) to acetylenes, or to acetylene equivalents such as optionally substituted cyclohexa-1,4-dienes or optionally substituted ethylenes bearing eliminatable substituents such as arylsulfonyl; or
- (h) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may be made by
 20 reacting aminomethylisoxazolines with 1,1-dihaloketone sulfonylhydrazones;
- (i) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may also be made by reacting azidomethyl isoxazolines with terminal alkynes using Cu(I) catalysis; and thereafter if necessary: (i) removing any protecting groups; (ii) forming a pharmaceutically-acceptable salt; (iii) forming an in-vivo hydrolysable ester.

- 34 -

- (a) Methods for converting substituents into other substituents are known in the art by using standard chemistry (see for example, Comprehensive Organic Functional Group Transformations (Pergamon), Katritzky, Meth-Cohn & Rees); for example:
- a hydroxy group may be converted into a silyloxy group; an azido or an acylamino or
- 5 thioacylamino group, for instance an acetamide group (optionally substituted or protected on the amido-nitrogen atom); into an acyloxy group, for instance an acetoxy group; a heterocyclamino group (optionally substituted or protected on the amino-nitrogen atom), for instance an isoxazol-3-ylamino group or a 1,2,5-thiadiazol-3-ylamino group; a heterocycl group linked through nitrogen (optionally substituted on a carbon other than a carbon atom
- 10 adjacent to the linking nitrogen ring atom), for instance an optionally substituted 1,2,3-triazol-1-yl group; or an amidino group, for instance an 1-(N-cyanoimino)ethylamino group; a hydroxy group may be alkylated to a methoxy group, a hydroxy group may be converted into a halo- group, or into a cyano- group; or into an alkylthio-, an arylthio- or a heteroarylthio-group (see, for example, Tet.Lett., 585, 1972); such conversions of the hydroxy group taking
- 15 place directly (for instance by acylation or Mitsunobu reaction) or through the intermediacy of one or more derivatives (for instance a mesylate or an azide); moreover, a hydroxy-group may be oxidized to a carbonyl group including a carboxylic acid group.
- an acyloxy group may be converted into a hydroxy group or into the groups that may be obtained from a hydroxy group (either directly or through the intermediacy of a hydroxy
- 20 group);
- a silyloxy group may be converted into a hydroxy group or into the groups that may be obtained from a hydroxy group (either directly or through the intermediacy of a hydroxy group);
- an acylamino group or thioacylamino group may be converted into another acylamino group
- 25 or thioacylamino group; or into a heterocyclamino group (optionally substituted or protected on the amino-nitrogen atom);
- a carboxylic acid group may be converted into an ester or an amide, an ester may be converted into a carboxylic acid or an amide, and an amide may be converted into an acid or a nitrile; a nitrile may be converted into a carboxylic acid or an amide or an imidate.
- 30 an imidate or a nitrile may be converted into a wide range of 5 membered heterocycles such as tetrazoles or 1,2,4-triazoles;

a carbonyl group can be reduced to a hydroxy group and a carboxylic acid group or a derivative thereof can be reduced to a carbonyl group or to a hydroxy group;

a carbonyl group may also be converted into a CF_2 group and a carboxylic acid group may be converted into a CF_3 group;

5 an alkylthio group may be oxidised to an alkylsulfinyl or alkylsulfonyl group;

a cyano group may be reduced to an amino group, a nitro group may be reduced to an amino group; a carbonyl group may be converted into a thiocarbonyl group (eg. using Lawesson's reagent) or a bromo group converted to an alkylthio group. It is possible in this way and in closely analogous ways using standard methods well known to skilled organic chemists to

10 interconvert compounds of formula (I).

(b)(i) Reaction (b)(i) (in which Y is initially hydroxy) is performed under Mitsunobu conditions, for example, in the presence of tri-n-butylphosphine and diethyl azodicarboxylate (DEAD) in an organic solvent such as THF, and in the temperature range 0°C - 60°C , but preferably at ambient temperature. Details of Mitsunobu reactions are contained in Tet. Letts.,
15 31, 699, (1990); The Mitsunobu Reaction, D.L.Hughes, Organic Reactions, 1992, Vol.42, 335-656 and Progress in the Mitsunobu Reaction, D.L.Hughes, Organic Preparations and Procedures International, 1996, Vol.28, 127-164.

(b)(ii) Reactions (b)(ii) are performed conveniently in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide or hydroxide, for example
20 sodium carbonate or potassium carbonate, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo-[5.4.0]undec-7-ene, the reaction is also preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, acetonitrile, tetrahydrofuran, 1,2-dimethoxyethane, *N,N*-dimethylformamide, *N,N*-dimethylacetamide, *N*-methylpyrrolidin-
25 2-one or dimethylsulfoxide at and at a temperature in the range 25 - 60°C .

When Y is chloro, the compound of the formula (II) may be formed by reacting a compound of the formula (II) wherein Y is hydroxy (hydroxy compound) with a chlorinating agent. For example, by reacting the hydroxy compound with thionyl chloride, in a temperature range of ambient temperature to reflux, optionally in a chlorinated solvent such as
30 dichloromethane or by reacting the hydroxy compound with carbon tetrachloride/triphenyl phosphine in dichloromethane, in a temperature range of 0°C to ambient temperature. A compound of the formula (II) wherein Y is chloro or iodo may also be prepared from a

- 36 -


compound of the formula (II) wherein Y is mesylate or tosylate, by reacting the latter compound with lithium chloride or lithium iodide and crown ether, in a suitable organic solvent such as THF, in a temperature range of ambient temperature to reflux

When Y is (1-4C)alkanesulfonyloxy or tosylate the compound (II) may be prepared by reacting the hydroxy compound with (1-4C)alkanesulfonyl chloride or tosyl chloride in the presence of a mild base such as triethylamine or pyridine.


When Y is a phosphoryl ester (such as $\text{PhO}_2\text{-P(O)-O-}$) or $\text{Ph}_2\text{-P(O)-O-}$ the compound (II) may be prepared from the hydroxy compound under standard conditions.

If not commercially available, compounds of the formula (III) may be prepared by procedures which are selected from standard chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the procedures described in the Examples. For example, standard chemical techniques are as described in Houben Weyl.

(c) by reaction of Q-Z wherein Z is an amine, urethane, or isocyanate with an N-epoxypropyl heterocycle (V). Epoxides of the formula (V) may be prepared from the corresponding N-allylheterocycle of formula (XII):



(V)



(XII)

Certain such epoxide and alkene intermediates are novel and are provided as a further feature of the invention. Asymmetric epoxidation may be used to give the desired optical isomer. Furthermore, a similar reaction to reaction (c) may be performed in which Q-Z (wherein Z is a amine group) is reacted with the epoxide (V) (optionally in the presence of an organic base), and the product is reacted with, for example, phosgene to form the oxazolidinone ring.

Alternatively, a precursor of the group HET may be incorporated in place of the group HET in the epoxide of formula (V).


Variations on this process in which the oxirane is replaced by an equivalent reagent $\text{X-CH}_2\text{CH(O-optionally protected)CH}_2\text{HET}$ where X is a displaceable group are also well known in the art.

- 37 -


Such reactions and the preparation of starting materials in within the skill of the ordinary chemist with reference to the above-cited documents disclosing analogous reactions and preparations.

In particular, compounds of the formula (II), and (IV) may be prepared by the skilled man, for example as described in International Patent Application Publication Nos. cited herein, and by analogous processes.

Compounds of the formula (II) wherein Y is hydroxy may be obtained as described in the references cited herein, for example, by reacting a compound Q-Z (IV) where Z is an amine, an isocyanate, or a urethane, especially a compound of the formula (IV, Z = NHCO₂R²¹) with a compound of formula (XIII):



(IV, Z = NHCO₂R²¹)



(XIII)

wherein R²¹ is (1-6C)alkyl or benzyl and R²² is (1-4C)alkyl or -S(O)_n(1-4C)alkyl where n is 0, 1 or 2. Preferably R²² is (1-4C)alkyl. Compounds of the formula (II), (IV), and (XIII) may be prepared by the skilled man, for example as described in International Patent Application Publication Nos. cited herein, the contents of which are hereby incorporated by reference, and by analogous processes.

Compounds of the formula Q-Z wherein Z is a urethane may be prepared by the skilled chemist, for example by analogous processes to those described in International Patent Application Publication Nos. WO 97/30995 and WO 97/37980. Compounds of the formula Q-Z wherein Z is an isocyanate may be prepared by the skilled chemist, for example by analogous processes to those described in Walter A. Gregory et al in J. Med. Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J. Med. Chem. 1992, 35, 1156-1165.

- 38 -

(d) Compounds of formula (II) wherein Y is HET as hereinabove defined or Y is a group that may be converted to HET, such as hydroxy, may be obtained by coupling together two appropriately substituted fragments to form a carbon-carbon bond in the place of the two substituents X and X' of (VI) and (VII) respectively. X and X' may be selected from
5 substituents such as chloro, bromo, iodo, trifluoromethanesulfonyloxy, trialkylstannyl, trialkoxysilyl, or a boronic acid residue provided that the selected substituents X and X' form a pair of complementary substituents known in the art to be suitable pairs of substituents for transition metal mediated reactions. For instance one of X and X' prime may be chloro and the other may be trimethylstannyl, as shown in the Scheme.

10 If not commercially available, the X and X' substituted fragments used as coupling partners in the transition metal mediated coupling reaction may be prepared by procedures that are selected from standard chemical techniques, techniques that are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the procedures described in the Examples. For example, standard chemical techniques are
15 described in Houben Weyl, Methoden der Organischen Chemie.

The chemistry of process (e) may also be utilised to prepare compounds of formula (II) wherein Y is hydroxy or a group that may be converted into a HET ring, and then process (b) or other suitable chemistry used to prepare compounds of formula (I).

(e) The reaction between thioacylhydrazides and acylating agents to form intermediate
20 acylthioacylhydrazides and subsequently 1,3,4-thiadiazoles is performed under conventional conditions, for instance as indicated in Comprehensive Heterocyclic Chemistry. Suitable acylating agents include acid chlorides and anhydrides. Either of the reaction components may constitute the thioacylhydrazide and the other constitutes the acylating agent, according to synthetic convenience.


25 The intermediate acylthioacylhydrazides may also be converted into 1,3,4-oxadiazoles. Carboxylic acid derivatives other than thioacylhydrazide are also well known in the art to be substrates for similar reactions leading to other C-linked 5-membered heterocycles containing 3 heteroatoms. For instance, acylhydrazides and amidrazones may be used in place of thioacylhydrazides and thioacylating agents such as methyl dithioacetate and imidolyating
30 agents such as ethyl acetimidate may be used in place of acylating agents. The products of such reactions are well known in the art. Thus, acylation of acylhydrazides and cyclisation of the resultant diacylhydrazides is known to give 1,3,4-oxadiazoles and acylation amidrazones

- 39 -

and cyclisation of the resultant acylamidrazones is known to give 1,2,4-triazoles. Such reactions are described in the literature as indicated in e.g. Comprehensive Heterocyclic Chemistry and are incorporated by reference into the process of method (e). It is further well known that these reactions, for instance the reaction between a (thio)acylating agent and a (thio)hydrazide proceed stepwise to give a cyclic product and that the reactions proceed through intermediates that can themselves be isolated under appropriate reaction conditions. Accordingly this method also includes a process in which an isolable intermediate for instance as di(thio)acylhydrazide is converted into a compound of formula (I) under the conditions already well known for reactions of this type. Moreover, an intermediate in this reaction may be produced under conditions where the cyclization to a compound of formula (I) proceeds spontaneously and without isolation of the intermediate compound, for instance in the conversion of a diacylhydrazide into a thiadiazole under conditions where monothio or dithio diacylhydrazides are formed from the diacylhydrazide and for example Lawesson's reagent. Accordingly this method also includes a process in which an intermediate of the process (e) is formed and spontaneously consumed to give a compound of formula (I) under the conditions already well known for reactions of process (e).

If not commercially available, compounds of the formula (VIII) and (IX) may be prepared by procedures which are selected from standard chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the procedures described in the Examples. For example, standard chemical techniques are as described in Houben Weyl.

Certain such thioacylhydrazide and acylating intermediates are novel and are provided as a further feature of the invention (R, Y and Y' suitable to give compounds of formula (I)).




- 40 -

(f) The reaction between thioamides and alpha-haloketones to form thiazoles is performed under conventional conditions, for instance as indicated in Comprehensive Heterocyclic Chemistry, The Chemistry of the Thioamide Group, or Thiazoles (Heterocyclic Chemistry, Weisberger). Suitable halogens include bromine and chlorine. It is well known that other
5 leaving groups may be suitable alternatives to the halogen of an alpha-haloketone, for instance methansulfonyloxy- or hydroxy-ketones or diazoketones may also be used in reaction (f). The regioisomer of thiazole obtained by this method depends on which reaction partner constitutes the thioamide and which reaction partner constitutes the alpha-(leaving-group)substituted-
ketone. In the reaction shown in the Scheme the thiazole produced is C2-linked. Carboxylic
10 acid derivatives other than thioamide are also well known in the art to be substrates for similar reactions leading to other C-linked 5-membered heterocycles. Such analogous reactions are described in e.g. Comprehensive Heterocyclic Chemistry and are incorporated by reference into the process of method (f). It is further well known that the reaction between an alpha-(leaving-group)substituted-ketone and a thioamide proceeds stepwise to give a 4-hydroxy-
15 4,5-dihydrothiazole as one of the intermediates and that this intermediate can be isolated under appropriate reaction conditions. Accordingly this method also includes a process in which an isolated 4-hydroxy-4,5-dihydrothiazole is converted into a compound of formula (I) under dehydrating conditions already well known for reactions of this type.

If not commercially available, compounds of the formula (X) and (XI) may be
20 prepared by procedures which are selected from standard chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the procedures described in the Examples. For example, standard chemical techniques are as described in Houben Weyl. Certain such thioamide and haloketone intermediates are novel and are provided as a further feature of the invention.

- 41 -



(g) The cycloaddition reaction to form 1,2,3 triazoles from the corresponding azide is performed under conventional conditions. . The reaction may use acetylenes or equivalent synthons that react as olefins and then eliminate the elements of a molecule to regenerate a double bond between the carbon atoms of the original olefin. Suitable olefins or their close analogues, which include those able to eliminate the elements of cyclopentadiene, of optionally substituted naphthalenes, of secondary amines, or of sulfinic or sulfenic acids, have been described in the literature as equivalents to or as synthons for alkynes. The method is illustrated in the Schemes.

- 10 (g) 4-Substituted 1,2,3-triazoles may be constructed from a primary amino compound according to the method of Sakai *et al.* by reacting it with sulfonylhydrazones of 1,1-dihalomethylketones. (see for example Sakai *et al.*, *Bull. Chem. Soc. Japan*, **1985**, 59, 179); as illustrated in the Schemes;

- (i) 4-Substituted 1,2,3-triazoles may be constructed from terminal alkynes in a mild and regioselective reaction according to the method of Sharpless. (see V.V. Rostov, L.G. Green, V.V. Folkin, and K.B. Sharpless, *Angew. Chem. Int. Ed.*, **2002**, 41, 2596); as illustrated in the Schemes; The preparation of suitable alkynes or their close analogues from simpler commercially available acetylenes such as acetylene itself or trimethylsilylacetylene is well-known in the chemical literature;


20

Compounds of the formula (II) wherein Y is azide may be obtained as described in the references cited herein (particularly in the section proceeding the discussion of protecting groups), for example from the corresponding compounds in which Y is hydroxy or mesylate.

- 42 -


The main synthetic routes are illustrated in the Schemes below (with Q as phenyl, and X, R and A defined with reference to analogous substituents defined elsewhere herein). The compounds of the invention may be prepared by analogous chemistry adapted from the Schemes. The Schemes also show the preparation of 1,2,3-triazoles via the azide (prepared
5 from the relevant hydroxy compound).

The Schemes may be genericised by the skilled man to apply to compounds within the present specification which are not specifically illustrated in the Schemes (for example to HET as a 6-membered ring as defined herein).




Scheme 1


- 43 -



Scheme 1a



Scheme 1b




5

10


- 44 -

Scheme 1c



5


Scheme 1d



10

Scheme 2

- 45 -



Scheme 3

5 Deprotection, salt formation or in-vivo hydrolysable ester formation may each be provided as a specific final process step.

The N-linked heterocycle can of course be prepared early in the overall synthesis, and then other functional groups changed.

Where Y is a displaceable group, suitable values for Y are for example, a halogeno or
10 sulfonyloxy group, for example a chloro, bromo, methanesulfonyloxy or toluene-4-sulfonyloxy group.

General guidance on reaction conditions and reagents may be obtained in Advanced Organic Chemistry, 4th Edition, Jerry March (publisher : J.Wiley & Sons), 1992. Necessary starting materials may be obtained by standard procedures of organic chemistry, such as
15 described in this process section, in the Examples section or by analogous procedures within the ordinary skill of an organic chemist. Certain references are also provided which describe the preparation of certain suitable starting materials, for example International Patent Application Publication No. WO 97/37980, the contents of which are incorporated here by reference. Processes analogous to those described in the references may also be used by the
20 ordinary organic chemist to obtain necessary starting materials.

- 46 -

The removal of any protecting groups, the formation of a pharmaceutically-acceptable salt and/or the formation of an in-vivo hydrolysable ester are within the skill of an ordinary organic chemist using standard techniques. Furthermore, details on these steps, for example the preparation of in-vivo hydrolysable ester prodrugs has been provided in the
5 section above on such esters, and in certain of the following non-limiting Examples.

When an optically active form of a compound of the formula (I) is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or
10 by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.

Similarly, when a pure regioisomer of a compound of the formula (I) is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a
15 standard procedure.

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof for use in a method of treatment of the human or animal body by therapy.

According to a further feature of the present invention there is provided a method for
20 producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof.

The invention also provides a compound of the formula (I), or a pharmaceutically-
25 acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament; and the use of a compound of the formula (I) of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal, such as man.

In order to use a compound of the formula (I), an in-vivo hydrolysable ester or a
30 pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, (hereinafter in this section relating to pharmaceutical composition "a compound of this invention") for the therapeutic (including prophylactic) treatment of

- 47 -

mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), an in-vivo hydrolysable ester or
5 a pharmaceutically-acceptable salt thereof, including a pharmaceutically-acceptable salt of an in-vivo hydrolysable ester, and a pharmaceutically-acceptable diluent or carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be
10 formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, aerosols (or sprays), drops and sterile injectable aqueous or oily solutions or suspensions.

In addition to the compounds of the present invention the pharmaceutical composition
15 of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, β -lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of
20 this invention may also contain or be co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between
25 1mg and 1g of a compound of this invention, preferably between 100mg and 1g of a compound. Especially preferred is a tablet or capsule which contains between 50mg and 800mg of a compound of this invention, particularly in the range 100mg to 500mg.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example an injection which contains
30 between 0.1% w/v and 50% w/v (between 1mg/ml and 500mg/ml) of a compound of this invention.

- 48 -

Each patient may receive, for example, a daily intravenous, subcutaneous or intramuscular dose of 0.5 mgkg^{-1} to 20 mgkg^{-1} of a compound of this invention, the composition being administered 1 to 4 times per day. In another embodiment a daily dose of 5 mgkg^{-1} to 20 mgkg^{-1} of a compound of this invention is administered. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient may receive a daily oral dose which may be approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

10 A pharmaceutical composition to be dosed intravenously may contain advantageously (for example to enhance stability) a suitable bactericide, antioxidant or reducing agent, or a suitable sequestering agent.

In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

Antibacterial Activity :

The pharmaceutically-acceptable compounds of the present invention are useful antibacterial agents having a good spectrum of activity in-vitro against standard Gram-positive organisms, which are used to screen for activity against pathogenic bacteria. Notably, the pharmaceutically-acceptable compounds of the present invention show activity against enterococci, pneumococci and methicillin resistant strains of *S.aureus* and coagulase negative staphylococci, together with haemophilus and moraxella strains. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system.

The (antibacterial) properties of the compounds of the invention may also be demonstrated and assessed in-vivo in conventional tests, for example by oral and/or intravenous dosing of a compound to a warm-blooded mammal using standard techniques.

The following results were obtained on a standard in-vitro test system. The activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot. Typically, compounds are active in the range 0.01 to $256 \mu\text{g/ml}$.

Staphylococci were tested on agar, using an inoculum of 10^4 CFU/spot and an

- 49 -

incubation temperature of 37°C for 24 hours - standard test conditions for the expression of methicillin resistance.

Streptococci and enterococci were tested on agar supplemented with 5% defibrinated horse blood, an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C in an atmosphere of 5% carbon dioxide for 48 hours - blood is required for the growth of some of the test organisms. Fastidious Gram negative organisms were tested in Mueller-Hinton broth, supplemented with hemin and NAD, grown aerobically for 24 hours at 37°C, and with an inoculum of 5×10^4 CFU/well.

For example, the following results were obtained for the compound of Example 1:

10 <u>Organism</u>		<u>MIC (μg/ml)</u>
Staphylococcus aureus:	MSQS	0.125
	MRQR	0.25
Streptococcus pneumoniae		0.125
Streptococcus pyogenes		0.125
15 Haemophilus influenzae		2
Moraxella catarrhalis		0.5

MSQS = methicillin sensitive and quinolone sensitive

MRQR = methicillin resistant and quinolone resistant

20

Certain intermediates and/or Reference Examples described hereinafter within the scope of the invention may also possess useful activity, and are provided as a further feature of the invention.

The invention is now illustrated but not limited by the following Examples in which
25 unless otherwise stated :-


- (i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
- (ii) operations were carried out at ambient temperature, that is typically in the range 18-26°C and without exclusion of air unless otherwise stated, or unless the skilled person
30 would otherwise work under an inert atmosphere;
- (iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;

- 50 -

- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra were generally determined in DMSO-d₆ unless otherwise stated using a Varian Gemini 2000 spectrometer operating at a field strength of 300 MHz, or a Bruker AM250 spectrometer operating at a field strength of 250 MHz; chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected];
- (vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate;
- (vii) in which the following abbreviations may be used :-
- DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; MPLC is medium pressure liquid chromatography; DMSO is dimethylsulfoxide; CDCl₃ is deuterated chloroform; MS is mass spectroscopy; ESP is electrospray; EI is electron impact; CI is chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol.

Each of the following Examples comprises an independent aspect of the invention.


Example 1: (5R)-3-(3-Fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of (5R)-3-(3-fluoro-4-(trimethylstannyl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-
 5 1,3-oxazolidin-2-one (442 mg, 1.0 mmol), 5-chloro-1,3,4-thiadiazole-2-carbonitrile (151 mg, 1.0 mmol), and triphenylarsine (32 mg, 0.1 mmol) in *N*-methyl-2-pyrrolidinone (5 ml) under an atmosphere of nitrogen was treated with tris(dibenzylideneacetone)dipalladium(0) (48 mg, 0.05 mmol) and then stirred under an atmosphere of nitrogen for 14 hours at 75°C. The solvent was removed under reduced pressure. A solution of the involatile dark oily residue in
 10 ethyl acetate (10 ml) was treated with an aqueous solution of potassium fluoride (2M; 10 ml). The mixture was vortexed for two minutes and then stirred for 15 minutes. The mixture was extracted with ethyl acetate (150 ml) and the extract was dried (MgSO₄). The dried extract was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (20 g) (dichloromethane to 2% methanol in
 15 dichloromethane gradient) to give the desired product (199 mg). MS (ESP) 372.06 (MH⁺) for C₁₅H₁₀FN₇O₂S. ¹H-NMR (DMSO-d₆) δ: 3.93 (dd, 1H); 4.27 (t, 1H); 4.86 (d, 2H); 5.16 (m, 1H); 7.27 (dd, 1H); 7.44 (m, 1H); 6.98 (t, 1H); 7.78 (s, 1H); 8.16 (s, 1H).

The intermediate for this compound was prepared as follows:

20 **(5R)-5-Azidomethyl-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one**



Methanesulfonyl chloride (17.9 ml) was added dropwise to a stirred solution of (5R)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyl-1,3-oxazolidin-2-one (55.8 g) and triethylamine (46.1
 25 ml) in dry dichloromethane (800 ml) under an atmosphere of dry nitrogen and maintained below room temperature by an ice-bath. The stirred reaction mixture was allowed to warm to room temperature during 3 hours and then washed sequentially with water and brine and then


- 52 -

dried (Na_2SO_4). Solvent was removed under reduced pressure to give the intermediate mesylate as a yellow solid (68 g) that was used without further purification.

A stirred solution in DMF (800 ml) of a mixture of the intermediate mesylate (68 g) and sodium azide (32.3 g) was heated at 75°C overnight. The mixture was allowed to cool to room temperature, diluted with water, and extracted twice with ethyl acetate. The combined extracts were washed sequentially with water and brine, and then dried (Na_2SO_4). Solvent was removed under reduced pressure to give a yellow oil that was purified by column chromatography on silica-gel. Elution with ethyl acetate-hexanes (1:1) gave the product azide as an off-white solid (49 g). The product could be further purified by trituration with ethyl acetate/hexanes.

$^1\text{H-NMR}$ (DMSO-d_6) δ : 3.57-3.64 (dd, 1H); 3.70-3.77 (dd, 1H); 3.81-3.87 (dd, 1H); 4.06 (t, 1H); 4.78-4.84 (m, 1H); 7.05-7.09 (ddd, 1H); 7.45 (dd, 1H); 7.68-7.74 (dd, 1H).


15 (5R)-3-(3-Fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A stirred solution in dioxan (300 ml) of a mixture of the (5R)-5-azidomethyl-3-(3-fluoro-4-iodophenyl)-1,3-oxazolidin-2-one (30 g) and bicyclo[2.2.1]heptadiene (30 ml) was heated under reflux overnight. The mixture was allowed to cool to room temperature and then evaporated to dryness under reduced pressure to give a brown solid. The brown solid was purified by column chromatography on silica-gel. Elution with methanol:chloroform (98:2 to 95:5) gave the product triazole as a pale yellow solid (20 g). The product could be further purified by trituration with dichloromethane/hexanes (1:1) to give an off-white solid.

25 $^1\text{H-NMR}$ (DMSO-d_6) δ : 3.86-3.92 (dd, 1H); 4.23 (t, 1H); 4.83 (d, 2H); 5.11-5.19 (m, 1H); 7.12-7.16 (dd, 1H); 7.47-7.51 (dd, 1H); 7.76 (s, 1H); 7.79-7.85 (dd, 1H); 8.16 (s, 1H).

(5R)-3-[3-Fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (5.39 g, 13.9 mmol) and hexamethylditin (5 g, 15.3 mmol) in dioxane (50 ml) under an atmosphere of nitrogen was treated with dichlorobis(triphenylphosphine)palladium (II) (487 mg, 0.69 mmol) and then stirred at 90°C under an atmosphere of nitrogen for 90 minutes. Silica gel (5 g) was added then the solvent removed under reduced pressure. The residual powder was placed on top of a silica gel column (100 g) and eluted (1% methanol in dichloromethane to 2.5% methanol in dichloromethane gradient) to give the desired product (4.545 g).

MS (ESP) 423, 425, 427 (MH⁺) for C₁₅H₁₉FN₄O₂Sn.


¹H-NMR (DMSO-d₆) δ: 0.32 (s, 9H); 3.90 (dd, 1H); 4.25 (t, 1H); 4.85 (d, 2H); 5.16 (m, 1H); 7.26 (dd, 1H); 7.33 (dd, 1H); 7.41 (dd, 1H); 7.78 (s, 1H); 8.18 (s, 1H).

15

The preparation of 5-chloro-[1,3,4]thiadiazole-2-carbonitrile is described in

- Gadwood, Robert C.; Barbachyn, Michael Robert; Toops, Dana Scott; Smith, Herman Walden; Vaillancourt, Valerie Ann. Preparation of azolylpiperazinyphenyloxazolidinones as antimicrobials. U.S. (1998), 34 pp.
20 CODEN: USXXAM US 5736545 A 19980407 CAN 128:270612 AN 1998:219349 CAPLUS
- Gadwood, Robert C.; Barbachyn, Michael R.; Toops, Dana S.; Smith, Herman W.; Vaillancourt, Valerie A. Preparation of 3-[4-(4-azolyl)-1-piperaziny]phenyl]oxazolidin-2-ones as bactericides. PCT Int. Appl. (1997), 79 pp.
25 CODEN: PIXXD2 WO 9730981 A1 19970828 CAN 127:278210 AN 1997:579705 CAPLUS

Example 2: (5R)-3-(3-Fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of (5R)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-
 5 1,3-oxazolidin-2-one (436 mg, 1.0 mmol), ethyl 5-chloro-1,3,4-thiadiazole-2-carboxylate (197 mg, 0.9 mmol), and tris(2-furyl)phosphine (24 mg, 0.1 mmol) in tetrahydrofuran (5 ml) under an atmosphere of nitrogen was treated with tris(dibenzylideneacetone)dipalladium(0) (47 mg, 0.05 mmol). The mixture was stirred under an atmosphere of nitrogen for 14 hours at 75°C. The solvent was removed under reduced pressure. A solution of the involatile dark oily
 10 residue in ethyl acetate (10 ml) was treated with an aqueous solution of potassium fluoride (2M; 10 ml). The mixture was vortexed for two minutes and then stirred for 15 minutes. The mixture was extracted with ethyl acetate (150 ml) and the extract was dried (MgSO₄). The dried extract was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (20 g) (dichloromethane to 2% methanol
 15 in dichloromethane gradient) to give the desired product (40 mg).

MS (ESP) 419.09 (MH⁺) for C₁₇H₁₅FN₆O₄S

¹H-NMR (DMSO-d₆) δ: 1.31 (t, 3H); 3.93 (dd, 1H); 4.26 (t, 1H); 4.39 (q, 2H); 4.80 (d, 2H); 5.14 (m, 1H); 7.50 (dd, 1H); 7.66 (dd, 1H); 7.70 (s, 1H); 8.12 (s, 1H); 8.32 (t, 1H).

20 The preparation of ethyl 2-chloro-[1,3,4]thiadiazole-5-carboxylate is described in

- Gadwood, Robert C.; Barbachyn, Michael R.; Toops, Dana S.; Smith, Herman W.; Vaillancourt, Valerie A. Preparation of 3-[4-(4-azolyl-1-piperazinyl)phenyl]oxazolidin-2-ones as bactericides. PCT Int. Appl. (1997), 79 pp. CODEN: PIXXD2 WO 9730981 A1 19970828 CAN 127:278210 AN

25 1997:579705 CAPLUS

- Demaree, Patricia; Doria, Marie Carmen; Muchowski, Joseph M. The reaction of certain α-diazocarbonyl compounds with thiophosgene and ethyl chlorodithioformate. Can. J. Chem. (1977), 55(2), 243-50. CODEN: CJCHAG CAN 88:6803 AN 1978:6803 CAPLUS

- 55 -


Example 3: (5R)-3-(4-(5-(Aminomethyl)-1,3-thiazol-2-yl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one

A mixture of (5R)-3-(3-fluoro-4-(trimethylstannyl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-
 5 1,3-oxazolidin-2-one (425 mg, 1.0 mmol), *tert*-butyl (2-bromo-1,3-thiazol-5-yl)methylcarbamate (293 mg, 1.0 mmol), copper (I) iodide (38 mg, 0.2 mmol) in DMF (3 ml) under an atmosphere of nitrogen was treated with tetrakis(triphenylphosphine) palladium (0) (56 mg, 0.05 mmol). The mixture was stirred under an atmosphere of nitrogen for 5 hours at 75°C. The reaction mixture was treated with an aqueous solution of potassium fluoride (2M;
 10 10 ml). Ethyl acetate (10 ml) was added and the mixture was vortexed for 5 minutes. The resulting precipitate was filtered off. The filtrate was extracted with ethyl acetate (100 ml) and the extract was dried (MgSO₄). The dried extract was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by chromatography on silica gel (20 g) (dichloromethane to 10% methanol in dichloromethane gradient) to give a
 15 yellow solid. This was dissolved in trifluoroacetic acid (5 ml) and stirred at room temperature for 20 minutes. The trifluoroacetic acid was removed *in vacuo* and the residue dissolved in DMSO (3 ml). This was purified by reverse phase chromatography (5% acetonitrile to 95% acetonitrile in water) to give the desired product (70 mg).

MS (ESP) 375.11 (MH⁺) for C₁₆H₁₅FN₆O₂S

20 ¹H-NMR (DMSO-d₆) δ: 3.95 (dd, 1H); 4.28 (t, 1H); 4.39 (q, 2H); 4.84 (d, 2H); 5.18 (m, 1H); 7.45 (dd, 1H); 7.63 (dd, 1H); 7.75 (s, 1H); 8.00 (s, 1H); 8.17 (s, 1H); 8.20 (t, 1H); 8.26 (s, 2H).

Example 4: (5R)-3-(3-Fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



A mixture of 2-fluoro-N'-acetyl-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-
 1,3-oxazolidin-3-yl)benzohydrazide (268 mg, 0.74 mmol), and Lawesson's reagent (597 mg,
 1.47 mmol) in anhydrous toluene (5 ml) under an atmosphere of nitrogen was heated under
 30 reflux overnight. The solvent was removed under reduced pressure and the residue was

- 56 -


purified by chromatography on C18 silica gel (Gilson HPLC) (dichloromethane to 2% methanol in dichloromethane gradient) to give the desired product (199 mg).

MS (ESP) 372.06 (MH^+) for $C_{15}H_{13}FN_6O_2S$.

1H -NMR (DMSO- d_6) δ : 2.82 (s, 3H); 3.99 (dd, 1H); 4.33 (t, 1H); 4.89 (d, 2H); 5.21 (m, 1H);
 5 7.52 (m, 1H); 7.69 (dd, 1H); 7.79 (s, 1H); 8.21 (s, 1H); 8.27 (m, 1H).

The intermediates for this compound was prepared as follows:

tert-Butyl 2-fluoro-4-((5*R*)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoate




10 *tert*-Butyl-4-((5*R*)-5-(azidomethyl)-1,3-oxazolidin-2-on-3-yl)-2-fluorobenzoate (15 g, 44.6 mmol) was dissolved in dioxane (100 ml). Bicyclo[2.2.1]hepta-2,5-diene (12.3g, 133.8 mmol) was added and the mixture was heated under reflux under nitrogen for 18 hours. The solvent was evaporated *in vacuo* and the residue was redissolved in dichloromethane and treated with hexanes to give a precipitate that was filtered, washed with ethyl acetate and
 15 collected as the desired product. The filtrate was concentrated and subjected to chromatography on silica gel eluting with 100% ethylacetate to give a further sample of the title compound (combined product weight 14.3 g).

MS (ESP) 363.22 (MH^+) for $C_{17}H_{19}FN_4O_4$.

1H -NMR (DMSO- d_6) δ : 1.55 (s, 9H); 3.97 (m, 1H); 4.28 (t, 1H); 4.86 (d, 2H); 5.20 (m, 1H);
 20 7.39 (dd, 1H); 7.52 (dd, 1H); 7.78 (s, 1H); 7.86 (t, 1H); 8.20 (s, 1H).


tert-Butyl 4-((5*R*)-5-(azidomethyl)-1,3-oxazolidin-2-on-3-yl)-2-fluorobenzoate



25 has been previously described in Gordeev, Mikhail F.; Luehr, Gary W.; Patel, Dinesh V.; Gadwood, Robert C. Preparation of N-acyl-3-aryl-2-oxooxazolidine-5-methanamines as bactericides. PCT Int. Appl. (2001), 134 pp. CODEN: PIXXD2 WO 0109107 A1 20010208

- 57 -


CAN 134:163021 AN 2001:101116 CAPLUS

2-Fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoic acid*tert*-Butyl 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoate

- 5 (14.2 g, 39.2 mmol) in dichloromethane was treated with 4N HCl in dioxane (5 equivalent) at 0°C, the mixture was stirred for 2 hours during which it was allowed to warm to room temperature. Solvent was evaporated under reduced pressure to give the desired product (11.9 g) in a form suitable for use without further purification.

MS (ESP) 307.14 (MH⁺) for C₁₃H₁₁FN₄O₄.

- 10 ¹H-NMR (DMSO-d₆) δ: 3.97 (m, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 5.20 (m, 1H); 7.39 (dd, 1H); 7.51 (dd, 1H); 7.78 (s, 1H); 7.90 (t, 1H); 8.20 (s, 1H); 13.11 (s, bd, 1H).

N'-Acetyl-2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzohydrazide

15


A mixture of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoic acid (450mg, 1.47mmol), HATU (565mg, 1.49mmol) and diisopropylethylamine (285mg, 2.21mmol) in dry DMF (5ml) was stirred at 0°C for 30 minutes, followed by the addition of acetic acid hydrazide (130.7mg, 1.76mmol). The reaction mixture was then

20 warmed up to room temperature and stirred for 2 hours. The mixture was diluted with dichloromethane (20ml), washed with saturated aqueous NaHCO₃ and brine, dried over anhydrous MgSO₄ and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (5% MeOH in dichloromethane) to give the desired product (289 mg).

- 25 MS (ESP+) 363.16 (MH⁺) for C₁₅H₁₅FN₆O₄.

¹H-NMR (DMSO-d₆) δ: 1.92 (s, 3H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.88 (d, 2H); 5.20 (m, 1H); 7.38 (dd, 1H); 7.53 (dd, 1H); 7.69 (t, 1H); 7.79 (s, 1H); 8.20 (s, 1H); 9.97 (s, 1H); 10.05 (s, 1H).


Example 5: (5R)-3-(3-Fluoro-4-(4-methyl-1,3-thiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one



- 5 A mixture of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzenecarbothioamide (30 mg, 0.094 mmol) and 1-chloroacetone (13 mg, 0.14 mmol) in dry DMF was stirred at 60°C overnight. Solvent was removed under reduced pressure and the residue was purified by reverse phase chromatography (Gilson MPLC C18 column, 5% to 95% acetonitrile in H₂O) to give the title compound (21 mg).
- 10 MS (ESP) 360.25 (MH⁺) for C₁₆H₁₄FN₅O₂S.
- ¹H-NMR (DMSO-d₆) δ: 2.47 (s, 3H); 3.99 (dd, 1H); 4.29 (t, 1H); 4.88 (d, 2H); 5.20 (m, 1H); 7.45 (s, 1H); 7.48 (dd, 1H); 7.64 (dd, 1H); 7.79 (s, 1H); 8.20 (s, 1H); 8.21 (m, 1H)..

The intermediates for this compound were prepared as follows:


- 15 2-Fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzamide




- A solution of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoic acid (2.5 g, 8.17 mmol) in dry dichloromethane (25 ml) at 0°C was treated with oxalyl chloride (1.56 g, 12.26 mmol) along with one drop of dimethylformaldehyde. The
- 20 reaction mixture was allowed to warm to room temperature and then stirred for one hour. Ammonium hydroxide (10 eq.) was then added and the reaction mixture was stirred overnight. The mixture was diluted with additional dichloromethane (20 ml) and then hexanes (30 ml) to give a precipitate that was isolated by filtration to give the desired product (1.5 g).
- MS (ESP) 306 (MH⁺) for C₁₃H₁₂FN₅O₃.
- 25 ¹H-NMR (DMSO-d₆) δ: 3.96 (m, 1H); 4.29 (t, 1H); 4.86 (d, 2H); 5.20 (m, 1H); 7.34 (m, 1H); 7.49 (dd, 1H); 7.60 (s, 2H); 7.74 (t, 1H); 7.78 (s, 1H); 8.20 (s, 1H).

2-Fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-

- 59 -

on-3-yl)benzenecarbothioamide

- A mixture of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzamide (95 mg, 0.31 mmol) and Lawesson's reagent (126 mg, 0.31 mmol) in dry
 5 toluene (1 ml) was sealed in a microwave reaction vessel and then irradiated in a Smith Microwave reactor at 160°C for 20 minutes. Solvent was evaporated under reduced pressure and the residue was purified by reverse phase chromatography (Gilson MPLC; C18 column; 5% to 95% acetonitrile in H₂O) to give the title compound (35 mg).
 MS (ESP+) 322.24 (MH⁺) for C₁₃H₁₂FN₅O₂S.
 10 ¹H-NMR (DMSO-d₆) δ: 3.94 (dd, 1H); 4.28 (t, 1H); 4.87 (d, 2H); 5.19 (m, 1H); 7.28 (dd, 1H); 7.45 (dd, 1H); 7.71 (t, 1H); 7.78 (s, 1H); 8.19 (s, 1H); 9.48 (s, 1H); 10.10 (s, 1H).


Example 6: (5R)-3-(3-Fluoro-4-(4-(trifluoromethyl)-1,3-thiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one

- 15 (5R)-3-(3-Fluoro-4-(4-hydroxy-4-(trifluoromethyl)-4,5-dihydro-1,3-thiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (25 mg, 0.058 mmol) in ethanol (3 ml) was heated to 150°C in a sealed tube for 7 days. The solvent was then evaporated and the residue was purified by column chromatography (silica gel; 5% MeOH in dichloromethane) to
 20 give the title compound (14 mg).
 MS (ESP) 414.18 (MH⁺) for C₁₆H₁₁F₄N₅O₂S.
¹H-NMR (DMSO-d₆) δ: 3.99 (dd, 1H); 4.29 (t, 1H); 4.88 (d, 2H); 5.20 (m, 1H); 7.45 (dd, 1H); 7.65 (dd, 1H); 7.79 (s, 1H); 8.10 (m, 1H); 8.21 (s, 1H); 8.38 (s, 1H).

- 60 -

The intermediate for this compound was prepared as follows:

(5R)-3-(3-Fluoro-4-(4-hydroxy-4-(trifluoromethyl)-4,5-dihydro-1,3-thiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one




5

A mixture of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzenecarbothioamide (30 mg, 0.094 mmol) and 1-bromo-3,3,3-trifluoroacetone (27 mg, 0.14 mmol) in dry DMF was stirred at 60°C overnight. Solvent was then evaporated under reduced pressure and the residue was purified by reverse phase chromatography (Gilson
10 MPLC; C18 column, 5% to 95% acetonitrile in H₂O) to give the title compound (32 mg).
MS (ESP) 432.07 (MH⁺) for C₁₆H₁₆F₄N₅O₃S.

¹H-NMR (DMSO-d₆) δ: 3.52 (d, 1H); 3.82 (d, 1H); 3.98 (dd, 1H); 4.30 (t, 1H); 4.88 (d, 2H); 5.20 (m, 1H); 7.49 (dd, 1H); 7.62 (dd, 1H); 7.79 (s, 1H); 8.01 (t, 1H); 8.21 (s, 1H).

15 **Example 7: (5-(2-Fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)phenyl)-1,3,4-thiadiazol-2-yl)acetonitrile**



The title compound was prepared from N'-(cyanoacetyl)-2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzohydrazide by the method described for Example 4.

20 MS (ESP+) 386.06 (MH⁺) for C₁₆H₁₂FN₇O₂S.


¹H-NMR (DMSO-d₆) δ: 4.01 (dd, 1H); 4.33 (t, 1H); 4.80 (s, 2H); 4.88 (dd, 2H); 5.20 (m, 1H); 7.58 (dd, 1H); 7.71 (dd, 1H); 7.79 (s, 1H); 8.20 (s, 1H); 8.30 (t, 1H).

The intermediate for this compound was prepared as follows:

25

- 61 -

N'-(Cyanoacetyl)-2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzohydrazide



A mixture of 2-fluoro-4-((5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)benzoic acid (450 mg, 1.47 mmol), HATU (671 mg, 1.764 mmol) and diisopropylethylamine (285 mg, 2.21 mmol) in dry DMF (5 ml) was stirred at 0°C for 30 minutes and then treated with cyanoacetohydrazide (219 mg, 2.21 mmol). The reaction mixture was then warmed up to room temperature and stirred for 2 hours. The mixture was diluted with dichloromethane (20 ml), washed with saturated aqueous NaHCO₃ and then
10 brine, dried over anhydrous MgSO₄ and evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (5% MeOH in dichloromethane) to give the desired product (300mg).


¹H-NMR (DMSO-d₆) δ: 2.71 (s, 2H); 3.96 (dd, 1H); 4.29 (t, 1H); 4.88 (d, 2H); 5.20 (m, 1H); 7.38 (dd, 1H); 7.53 (dd, 1H); 7.69 (t, 1H); 7.79 (s, 1H); 8.20 (s, 1H); 10.32 (s, 1H);
15 10.44 (s, 1H).

- 62 -

Claims

1. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof,

5



(I)

10 wherein

HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, containing either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on a C atom, other than a C atom adjacent to the linking N atom, by an oxo or thioxo group;

15 and/or which ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by a substituent Rs wherein;

R_s is selected from the group:

(R_{sa}): halogen, (1-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, amino, (1-4C)alkylamino, di-(1-4C)alkylamino,

20 (2-4C)alkenylamino, (1-4C)alkylcarbonylamino, (1-4C)alkylthiocarbonylamino, (1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH- or (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2);

or R_s is selected from the group

(R_{sb}): (1-4C)alkyl group which is optionally substituted by one substituent selected from
 25 hydroxy, (1-4C)alkoxy, amino, cyano, azido, (2-4C)alkenyloxy, (1-4C)alkylcarbonyl, (1-4C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkyl-SO₂-NH-, (1-4C)alkylcarbonylamino, (1-4C)alkylthiocarbonylamino, (1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH-, (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2), (3-6C)cycloalkyl, (3-6C)cycloalkenyl,

30 or an N-linked 5-membered heteroaryl ring, which ring contains either (i) 1 to 3 further nitrogen heteroatoms or (ii) a further heteroatom selected from O and S together with an optional further nitrogen heteroatom; which ring is optionally substituted on a carbon atom by

- 63 -

an oxo or thioxo group; and/or the ring is optionally substituted on a carbon atom by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl;

or Rs is selected from a group of formula (Rsc1) to (Rsc3) :-

5 (Rsc1): a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen or carbon atom; or

(Rsc2): a saturated or unsaturated 5-membered monocyclic ring containing 1 heteroatom selected from O, N and S (optionally oxidised), and linked via a ring nitrogen
10 atom if the ring is not thereby quaternised, or a ring carbon atom; or

(Rsc3): a saturated or unsaturated 6- to 8-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O, N and S (optionally oxidised), and linked via a ring nitrogen atom if the ring is not thereby quaternised, or a ring carbon atom;

wherein said rings in (Rsc1) to (Rsc3) are optionally substituted on an available carbon atom
15 by 1 or 2 substituents independently selected from hydroxy, (1-4C)alkoxy, amino, cyano, azido, (2-4C)alkenyloxy, (1-4C)alkylcarbonyl, (1-4C)alkoxycarbonyl, (1-4C)alkylamino, (2-4C)alkenylamino, (1-4C)alkyl-SO₂-NH-, (1-4C)alkylcarbonylamino, (1-4C)alkylthiocarbonylamino, (1-4C)alkyl-OCO-NH-, (1-4C)alkyl-NH-CO-NH-, (1-4C)alkyl-NH-CS-NH-, (1-4C)alkyl-SO₂-NH-, (1-4C)alkyl-S(O)_q- (wherein q is 0, 1 or 2),
20 (3-6C)cycloalkyl or (3-6C)cycloalkenyl;

or Rs is selected from the group

(Rsd): cyano, nitro, azido, formyl, (1-4C)alkylcarbonyl or (1-4C)alkoxycarbonyl;
and wherein at each occurrence of an Rs substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (Rsa), (Rsb) or (Rsc1) to (Rsc3) each such moiety is

25 optionally further substituted on an available carbon atom with one or more substituents independently selected from F, Cl and Br and/or by one cyano group;

and/or which ring is optionally substituted on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl; or


30 HET is an N-linked 6-membered di-hydro-heteroaryl ring containing up to three nitrogen heteroatoms in total (including the linking heteroatom), which ring is substituted on a suitable C atom, other than a C atom adjacent to the linking N atom, by oxo or thioxo and/or which

- 64 -


ring is optionally substituted on any available C atom, other than a C atom adjacent to the linking N atom, by one or two substituents Rs, wherein Rs is as hereinbefore defined, and/or on an available nitrogen atom (provided that the ring is not thereby quaternised) by (1-4C)alkyl; and wherein at each occurrence of alkyl, alkenyl and cycloalkyl HET substituents,

5 each is optionally substituted with one or more substituents independently selected from F, Cl and Br and/or by one cyano group;


Q is selected from Q1 to Q10 :-




Q1




Q2




Q3




Q4




Q5




Q6




Q7



Q8



Q9



Q10







20 wherein R² and R³ are independently hydrogen or fluoro;
 wherein A₁ is carbon or nitrogen; B₁ is O or S (or, in Q₉ only, NH); X_q is O, S or N-R¹
 (wherein R¹ is hydrogen, (1-4C)alkyl or hydroxy-(1-4C)alkyl); and wherein

- 65 -

in Q7 each A₁ is independently selected from carbon or nitrogen, with a maximum of 2 nitrogen heteroatoms in the 6-membered ring, and Q7 is linked to T via any of the A₁ atoms (when A₁ is carbon), and linked in the 5-membered ring via the specified carbon atom, or via A₁ when A₁ is carbon; Q8 and Q10 are linked to T via either of the specified carbon atoms in the 5-membered ring, and linked in the benzo-ring via either of the two specified carbon atoms on either side of the linking bond shown; and Q9 is linked via either of the two specified carbon atoms on either side of the linking bond shown;

T is an optionally substituted C-linked (fully unsaturated) 5-membered heteroaryl ring system containing 1, 2 or 3 heteroatoms drawn in combination from O, N, or S, optionally substituted by one or more substituents independently selected from R^{4h}, R^{5h} and R^{6h} defined hereinafter;

T is preferably selected from the following groups of formula (TAa1) to (TAa6) below (wherein AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1 and CY2 are defined hereinbelow);



20 wherein :

R^{6h} is selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, (1-4C)alkanoyl, carbamoyl and cyano;

R^{4h} and R^{5h} are independently selected from hydrogen, halo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (1-4C)alkylS(O)_q (q is 0, 1 or 2), (1-4C)alkanoyl, (1-4C)alkoxycarbonyl,

25 benzyloxy-(1-4C)alkyl, (2-4C)alkanoylamino, -CONRcRv and -NRcRv wherein any


- 66 -

(1-4C)alkyl group contained in the preceding values for R^{4h} and R^{5h} is optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 5 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (not on C1 of an alkoxy group, and excluding geminal disubstitution); wherein R_v is hydrogen or (1-4C)alkyl and R_c is as hereinafter defined;

R^{4h} and R^{5h} may further be independently selected from (1-4C)alkyl {optionally substituted by up to three substituents independently selected from hydroxy (excluding geminal 10 disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (excluding geminal disubstitution); wherein R_v is hydrogen or (1-4C)alkyl}; R_c is as hereinafter defined; and wherein any (1-4C)alkyl group contained in the immediately preceding optional substituents (when 15 R^{4h} and R^{5h} are independently (1-4C)alkyl) is itself optionally substituted by up to three substituents independently selected from hydroxy (not on C1 of an alkoxy group, and excluding geminal disubstitution), oxo, trifluoromethyl, cyano, nitro, (1-4C)alkoxy, (2-4C)alkanoyloxy, hydroxyimino, (1-4C)alkoxyimino, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), (1-4C)alkylSO₂-NR_v-, (1-4C)alkoxycarbonyl, -CONR_cR_v, and -NR_cR_v (not on C1 of an 20 alkoxy group, and excluding geminal disubstitution); wherein R_v is hydrogen or (1-4C)alkyl and R_c is as hereinafter defined;

or R^{4h} is selected from one of the groups in (TAaa) to (TAac) below, or (where appropriate) one of R^{4h} and R^{5h} is selected from the above list of R^{4h} and R^{5h} values, and the other is selected from one of the groups in (TAaa) to (TAac) below :-

25 (TAaa) a group of the formula (TAaa1)



(TAaa1)

wherein Z⁰ is hydrogen or (1-4C)alkyl;

- 67 -

X^0 and Y^0 are independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkoxycarbonyl, halo, cyano, nitro, (1-4C)alkylS(O)_q- (q is 0, 1 or 2), RvRwNSO₂-, trifluoromethyl, pentafluoroethyl, (1-4C)alkanoyl and -CONRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl]; or

- 5 one of X^0 and Y^0 is selected from the above list of X^0 and Y^0 values, and the other is selected from phenyl, phenylcarbonyl, -S(O)_q-phenyl (q is 0, 1 or 2), N-(phenyl)carbamoyl, phenylaminosulfonyl, AR₂, (AR₂)-CO-, (AR₂)-S(O)_q- (q is 0, 1 or 2), N-(AR₂)carbamoyl and (AR₂)aminosulfonyl; wherein any phenyl group in (*TAaa*) may be optionally substituted by up to three substituents independently selected from (1-4C)alkyl, cyano, trifluoromethyl, nitro, halo and (1-4C)alkylsulfonyl;
- 10 (*TAab*) an acetylene of the formula \equiv -H or \equiv -(1-4C)alkyl;
 (*TAac*) -X¹-Y¹-AR₂, -X¹-Y¹-AR_{2a}, -X¹-Y¹-AR_{2b}, -X¹-Y¹-AR₃, -X¹-Y¹-AR_{3a} or -X¹-Y¹-AR_{3b};
 wherein X¹ is a direct bond or -CH(OH)- and
- 15 Y¹ is -(CH₂)_m-, -(CH₂)_n-NH-(CH₂)_m-, -CO-(CH₂)_m-, -CONH-(CH₂)_m-, -C(=S)NH-(CH₂)_m- or -C(=O)O-(CH₂)_m-;
 or wherein X¹ is -(CH₂)_n- or -CH(Me)-(CH₂)_m- and
 Y¹ is -(CH₂)_m-NH-(CH₂)_m-, -CO-(CH₂)_m-, -CONH-(CH₂)_m-, -C(=S)NH-(CH₂)_m-, -C(=O)O-(CH₂)_m- or -S(O)_q-(CH₂)_m-;
- 20 or wherein X¹ is -CH₂O-, -CH₂NH- or -CH₂N((1-4C)alkyl)- and
 Y¹ is -CO-(CH₂)_m-, -CONH-(CH₂)_m- or -C(=S)NH-(CH₂)_m-; and additionally Y¹ is -SO₂- when X¹ is -CH₂NH- or -CH₂N((1-4C)alkyl)-, and Y¹ is -(CH₂)_m- when X¹ is -CH₂O- or -CH₂N((1-4C)alkyl)-; wherein n is 1, 2 or 3; m is 0, 1, 2 or 3 and q is 0, 1 or 2; and when Y¹ is -(CH₂)_m-NH-(CH₂)_m- each m is independently selected from 0, 1, 2 or 3;
- 25 wherein Rc is selected from groups (Rc1) to (Rc5) :-
 (*Rc1*) (1-6C)alkyl {optionally substituted by one or more (1-4C)alkanoyl groups (including geminal disubstitution) and/or optionally monosubstituted by cyano, (1-4C)alkoxy, trifluoromethyl, (1-4C)alkoxycarbonyl, phenyl (optionally substituted as for AR₁ defined hereinafter), (1-4C)alkylS(O)_q- (q is 0, 1 or 2); or, on any but the first carbon atom of the
- 30 (1-6C)alkyl chain, optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy and fluoro, and/or optionally monosubstituted by oxo, -NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or

- 68 -

(1-4C)alkyl], (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylS(O)_pNH- or (1-4C)alkylS(O)_p-((1-4C)alkyl)N- (p is 1 or 2));

(Rc2) R¹³CO-, R¹³SO₂- or R¹³CS-

5 wherein R¹³ is selected from (Rc2a) to (Rc2e) :-

(Rc2a) AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b, AR4, AR4a, CY1, CY2;

(Rc2b) hydrogen, (1-4C)alkoxycarbonyl, trifluoromethyl, -NR_vR_w [wherein R_v is hydrogen or (1-4C)alkyl; R_w is hydrogen or (1-4C)alkyl], ethenyl, 2-(1-4C)alkylethenyl, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-nitroethenyl, 2-nitro-2-

10 ((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, 2-(AR2a)ethenyl;

(Rc2c) (1-10C)alkyl

{optionally substituted by one or more groups (including geminal disubstitution) each independently selected from hydroxy, (1-10C)alkoxy, (1-4C)alkoxy-(1-4C)alkoxy,

15 (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxy, (1-4C)alkanoyl, carboxy, phosphoryl [-O-P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], and amino; and/or optionally substituted by one group selected from phosphonate [phosphono, -P(O)(OH)₂, and mono- and

20 derivatives thereof], cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, (1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl,

(1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p-((1-4C)alkyl)N-, fluoro(1-4C)alkylS(O)_pNH-,

25 fluoro(1-4C)alkylS(O)_p((1-4C)alkyl)N-, (1-4C)alkylS(O)_q- [the (1-4C)alkyl group of (1-4C)alkylS(O)_q- being optionally substituted by one substituent selected from hydroxy, (1-4C)alkoxy, (1-4C)alkanoyl, phosphoryl [-O-P(O)(OH)₂, and mono- and di-(1-4C)alkoxy derivatives thereof], phosphiryl [-O-P(OH)₂ and mono- and di-(1-4C)alkoxy derivatives thereof], amino, cyano, halo, trifluoromethyl, (1-4C)alkoxycarbonyl, (1-4C)alkoxy-

30 (1-4C)alkoxycarbonyl, (1-4C)alkoxy-(1-4C)alkoxy-(1-4C)alkoxycarbonyl, carboxy,


- 69 -

(1-4C)alkylamino, di((1-4C)alkyl)amino, (1-6C)alkanoylamino, (1-4C)alkoxycarbonylamino, N-(1-4C)alkyl-N-(1-6C)alkanoylamino, (1-4C)alkylaminocarbonyl, di((1-4C)alkyl)aminocarbonyl, (1-4C)alkylS(O)_pNH-, (1-4C)alkylS(O)_p-((1-4C)alkyl)N-, (1-4C)alkylS(O)_q-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q- and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups], CY1, CY2, AR1, AR2, AR3, AR1-O-, AR2-O-, AR3-O-, AR1-S(O)_q-, AR2-S(O)_q-, AR3-S(O)_q-, AR1-NH-, AR2-NH-, AR3-NH- (p is 1 or 2 and q is 0, 1 or 2), and also AR2a, AR2b, AR3a and AR3b versions of AR2 and AR3 containing groups};

(Rc2d) R¹⁴C(O)O(1-6C)alkyl wherein R¹⁴ is AR1, AR2, (1-4C)alkylamino (the (1-4C)alkyl group being optionally substituted by (1-4C)alkoxycarbonyl or by carboxy), benzyloxy-(1-4C)alkyl or (1-10C)alkyl {optionally substituted as defined for (Rc2c)};

(Rc2e) R¹⁵O- wherein R¹⁵ is benzyl, (1-6C)alkyl {optionally substituted as defined for (Rc2c)}, CY1, CY2 or AR2b;

(Rc3) hydrogen, cyano, 2-cyanoethenyl, 2-cyano-2-((1-4C)alkyl)ethenyl, 2-((1-4C)alkylaminocarbonyl)ethenyl, 2-((1-4C)alkoxycarbonyl)ethenyl, 2-nitroethenyl, 2-nitro-2-((1-4C)alkyl)ethenyl, 2-(AR1)ethenyl, 2-(AR2)ethenyl, or of the formula **(Rc3a)**

**(Rc3a)**

wherein X⁰⁰ is -OR¹⁷, -SR¹⁷, -NHR¹⁷ and -N(R¹⁷)₂;

wherein R¹⁷ is hydrogen (when X⁰⁰ is -NHR¹⁷ and -N(R¹⁷)₂), and R¹⁷ is (1-4C)alkyl, phenyl or AR2 (when X⁰⁰ is -OR¹⁷, -SR¹⁷ and -NHR¹⁷); and R¹⁶ is cyano, nitro, (1-4C)alkylsulfonyl, (4-7C)cycloalkylsulfonyl, phenylsulfonyl, (1-4C)alkanoyl and (1-4C)alkoxycarbonyl;

(Rc4) trityl, AR1, AR2, AR2a, AR2b, AR3, AR3a, AR3b;

(Rc5) RdOC(Re)=CH(C=O)-, RfC(=O)C(=O)-, RgN=C(Rh)C(=O)- or

RiNHC(Rj)=CHC(=O)- wherein Rd is (1-6C)alkyl; Re is hydrogen or (1-6C)alkyl, or Rd and Re together form a (3-4C)alkylene chain; Rf is hydrogen, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, -NRvRw [wherein Rv is hydrogen or (1-4C)alkyl; Rw is hydrogen or (1-4C)alkyl], (1-6C)alkoxy, (1-6C)alkoxy(1-6C)alkoxy, hydroxy(2-6C)alkoxy, (1-4C)alkylamino(2-6C)alkoxy, di-(1-4C)alkylamino(2-6C)alkoxy; Rg is (1-6C)alkyl, hydroxy or (1-6C)alkoxy; Rh is hydrogen or (1-6C)alkyl; Ri is hydrogen, (1-6C)alkyl, AR1,

- 70 -

AR2, AR2a, AR2b and Rj is hydrogen or (1-6C)alkyl;

wherein

AR1 is an optionally substituted phenyl or optionally substituted naphthyl;

AR2 is an optionally substituted 5- or 6-membered, fully unsaturated (i.e with the maximum
5 degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms
independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and
linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised;

AR2a is a partially hydrogenated version of AR2 (i.e. AR2 systems retaining some, but not
the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen
10 atom if the ring is not thereby quaternised;

AR2b is a fully hydrogenated version of AR2 (i.e. AR2 systems having no unsaturation),
linked via a ring carbon atom or linked via a ring nitrogen atom;

AR3 is an optionally substituted 8-, 9- or 10-membered, fully unsaturated (i.e with the
maximum degree of unsaturation) bicyclic heteroaryl ring containing up to four heteroatoms
15 independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and
linked via a ring carbon atom in either of the rings comprising the bicyclic system;

AR3a is a partially hydrogenated version of AR3 (i.e. AR3 systems retaining some, but not
the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen
atom if the ring is not thereby quaternised, in either of the rings comprising the bicyclic
20 system;

AR3b is a fully hydrogenated version of AR3 (i.e. AR3 systems having no unsaturation),
linked via a ring carbon atom, or linked via a ring nitrogen atom, in either of the rings
comprising the bicyclic system;

AR4 is an optionally substituted 13- or 14-membered, fully unsaturated (i.e with the
25 maximum degree of unsaturation) tricyclic heteroaryl ring containing up to four heteroatoms
independently selected from O, N and S (but not containing any O-O, O-S or S-S bonds), and
linked via a ring carbon atom in any of the rings comprising the tricyclic system;

AR4a is a partially hydrogenated version of AR4 (i.e. AR4 systems retaining some, but not
the full, degree of unsaturation), linked via a ring carbon atom, or linked via a ring nitrogen
30 atom if the ring is not thereby quaternised, in any of the rings comprising the tricyclic system;

CY1 is an optionally substituted cyclobutyl, cyclopentyl or cyclohexyl ring;


CY2 is an optionally substituted cyclopentenyl or cyclohexenyl ring.

- 71 -

2. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof,
wherein Q is selected from Q1, Q2, Q4, Q6 and Q9.

3. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, wherein T is selected from the groups of formula (TAa1) to (TAa6).

4. A compound of formula (IB), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof,



(IB)

wherein HET is 1,2,3-triazole (especially 1,2,3-triazol-1-yl), 1,2,4-triazole (especially 1,2,4-triazol-1-yl) and tetrazole (preferably tetrazol-2-yl) or HET is a di-hydro version of pyrimidine, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine and pyridine;
R² and R³ are independently hydrogen or fluoro; and
T is selected from (TAa1 to TAa6).

5. A compound of formula (IB) as claimed in claim 4, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, wherein
wherein HET is 1,2,3-triazole (especially 1,2,3-triazol-1-yl), 1,2,4-triazole (especially 1,2,4-triazol-1-yl) or tetrazole (preferably tetrazol-2-yl);
R² and R³ are independently hydrogen or fluoro; and
T is selected from (TAa1 & 2).

6. A compound of the formula (I) as claimed in any preceding claim, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, wherein R_s is selected

- 72 -

from fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, bromomethyl, cyanomethyl, cyano, amino, azido, alkylthioalkyl such as methylthiomethyl and 2-propynyl.

7. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, for use as a medicament.

8. The use of a compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof, in the manufacture of a medicament for use in the production of an antibacterial effect in a warm blooded animal.

10

9. A pharmaceutical composition which comprises a compound of the formula (I) as claimed in claim 1, or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof, and a pharmaceutically-acceptable diluent or carrier.


15 10. A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof for use in a method of treatment of the human or animal body by therapy.

11. A method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof

12. A process for the manufacture of a compound of the formula (I) comprising one or more of the processes (a) to (i) below:

(a) by modifying a substituent in or introducing a substituent into another compound of formula (I);

(b) by reaction of a compound of formula (II) :



- 73 -

wherein Y is a displaceable group with a compound of the formula (III) :

HET

(III)


wherein HET is HET-H free-base form or HET⁻ anion formed from the free base form;

- 5 (c) by reaction of a compound of the formula (IV) :

Q-Z

(IV)


wherein Z is an isocyanate, amine or urethane group with an epoxide of the formula (V):



10

(V)

- (d) by reaction of a compound of formula (VI) :



(VI)

- 15 wherein Y' is a group HET as hereinabove defined, X is a replaceable substituent located at a position substituted by T in any of the aromatic embodiments Q1 – Q8 of Qn as hereinabove defined for Q, but with X in place of the substituent T, with a compound of the formula (VII) :


T-X'

(VII)

- 20 wherein T-X' is a five-membered heterocycle with 1-3 heteroatoms drawn in combination from O, N, and S and X' is a replaceable C-linked substituent; wherein the substituents X and X' are chosen to be complementary pairs of substituents known in the art to be suitable as complementary substrates for coupling reactions catalysed by transition metals such as palladium(0);


- 25 (e) by reaction of a compound of formula (VIII):

- 74 -



(VIII)


wherein Y' is a group HET as defined herein above and X1 and X2 here are independently optionally substituted heteroatoms drawn in combination from O, N, and S such that C(X1)X2
 5 constitutes a substituent that is a carboxylic acid derivative substituent located at a position substituted by T in any of the aromatic embodiments Q1 – Q10 of Qn as hereinabove defined for Q with a compound of the formula (IX) and X3 and X4 are independently optionally substituted heteroatoms drawn in combination from O, N, and S:



(IX)

10 and wherein one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted hydrazide, thiohydrazide, or amidrazone, and the other one of C(X1)X2 and C(X3)X4 constitutes an optionally substituted acylating, thioacylating, or imidoylating agent such that C(X1)X2 and C(X3)X4 may be condensed together to form a 5-membered heterocycle containing 3
 15 heteroatoms drawn in combination from O, N, and S, for instance thiadiazole, by methods well-known in the art;


(f) by reaction of a compound of formula (X):



(X)

20 wherein Y' is a group HET as defined herein above and C(X5)X6 constitutes a substituent located at a position substituted by T in any of the aromatic embodiments Q1 – Q8 of Qn as hereinabove defined for Q with a compound of the formula (XI):

- 75 -



(XI)

wherein one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted alpha-(leaving-group-substituted)ketone, wherein the leaving group is for example a halo-group or an (alkyl or aryl)-sulfonyloxy-group, and the other one of C(X5)X6 and C(X7)X8 constitutes an optionally substituted amide, thioamide, or amidine, such that C(X5)X6 and C(X7)X8 are groups that may be condensed together to form a 5-membered heterocycle containing 2 heteroatoms drawn in combination from O, N, and S, for instance thiazole, by methods well-known in the art;

- 10 (g) for HET as optionally substituted 1,2,3-triazoles compounds of formula (I) may be made by cycloaddition via the azide (wherein e.g. Y in (II) is azide) to acetylenes, or to acetylene equivalents such as optionally substituted cyclohexa-1,4-dienes or optionally substituted ethylenes bearing eliminatable substituents such as arylsulfonyl;
- (h) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may be made by
15 reacting aminomethylisoxazolines with 1,1-dihaloketone sulfonylhydrazones;
- (i) for HET as 4-substituted 1,2,3-triazole compounds of formula (I) may also be made by reacting azidomethyl isoxazolines with terminal alkynes using Cu(1) catalysis; and thereafter if necessary: (i) removing any protecting groups; (ii) forming a pharmaceutically-acceptable salt; (iii) forming an in-vivo hydrolysable ester.

20

13. A compound selected from

(5R)-3-(3-Fluoro-4-(5-cyano-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5R)-3-(3-Fluoro-4-(5-ethoxycarbonyl-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-
25 1-ylmethyl)-1,3-oxazolidin-2-one;

(5R)-3-(4-(5-(Aminomethyl)-1,3-thiazol-2-yl)-3-fluorophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

(5R)-3-(3-Fluoro-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one;

30 (5R)-3-(3-Fluoro-4-(4-methyl-1,3-thiazol-2-yl)phenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-

- 76 -

1,3-oxazolidin-2-one;

(5*R*)-3-(3-Fluoro-4-(4-(trifluoromethyl)-1,3-thiazol-2-yl)phenyl)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one; and

(5-(2-Fluoro-4-((5*R*)-5-(1*H*-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-on-3-yl)phenyl)-

5 1,3,4-thiadiazol-2-yl)acetonitrile;

or a pharmaceutically-acceptable salt or an in-vivo hydrolysable ester thereof.

INTERNATIONAL SEARCH REPORT

PCT/GB 02/04796

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/10 A61K31/433 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3 318 878 A (DUNN GEORGE L) 9 May 1967 (1967-05-09) claim 1	1-13
Y	WO 99 64416 A (ZENECA LTD ;GRAVESTOCK MICHAEL BARRY (GB)) 16 December 1999 (1999-12-16) claim 1	1-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 January 2003

Date of mailing of the international search report

24/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seelmann, I

INTERNATIONAL SEARCH REPORT

PCT/GB 02/04796

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PAE A N ET AL: "Synthesis and in vitro activity of new oxazolidinone antibacterial agents having substituted isoxazoles" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 18, 20 September 1999 (1999-09-20), pages 2679-2684, XP004179951 ISSN: 0960-894X abstract; tables 1,2 -----	1-13
Y	WO 93 23384 A (UPJOHN CO ; HUTCHINSON DOUGLAS K (US); BRICKNER STEVEN JOSEPH (US);) 25 November 1993 (1993-11-25) claim 1 -----	1-13

INTERNATIONAL SEARCH REPORT

PCT/GB 02/04796

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3318878	A	09-05-1967	BE 696823 A	10-10-1967
			DE 1695689 A1	15-07-1971
			DK 114062 B	27-05-1969
			FR 6293 M	09-09-1968
			GB 1109588 A	10-04-1968
			NL 6703212 A	16-10-1967
WO 9964416	A	16-12-1999	AU 753865 B2	31-10-2002
			AU 4156599 A	30-12-1999
			BR 9910915 A	06-03-2001
			CA 2332831 A1	16-12-1999
			CN 1304410 T	18-07-2001
			EP 1082322 A2	14-03-2001
			WO 9964416 A2	16-12-1999
			HU 0103404 A2	29-05-2002
			JP 2002517497 T	18-06-2002
			NO 20006149 A	02-02-2001
WO 9323384	A	25-11-1993	AT 219770 T	15-07-2002
			AU 668733 B2	16-05-1996
			AU 4287793 A	13-12-1993
			CA 2133079 A1	25-11-1993
			CN 1079964 A ,B	29-12-1993
			CZ 9402505 A3	16-08-1995
			DE 69332061 D1	01-08-2002
			DE 69332061 T2	07-11-2002
			DK 640077 T3	14-10-2002
			EP 0640077 A1	01-03-1995
			FI 945246 A	08-11-1994
			HU 72296 A2	29-04-1996
			HU 9500659 A3	28-11-1995
			IL 105555 A	15-07-1998
			JP 3255920 B2	12-02-2002
			JP 7506829 T	27-07-1995
			MX 9302665 A1	01-11-1993
			NO 944237 A	04-01-1995
			PL 174909 B1	30-10-1998
			PL 174850 B1	30-09-1998
			RU 2105003 C1	20-02-1998
			SK 133794 A3	07-06-1995
			WO 9323384 A1	25-11-1993
			US 5547950 A	20-08-1996
			US 5700799 A	23-12-1997
			ZA 9302855 A	24-10-1994